<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Transcranial magnetic stimulation (TMS) for schizophrenia - Dougall, N - 2015 | Cochrane Library</title> <meta content="Transcranial magnetic stimulation (TMS) for schizophrenia - Dougall, N - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006081.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Transcranial magnetic stimulation (TMS) for schizophrenia - Dougall, N - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006081.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006081.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Transcranial magnetic stimulation (TMS) for schizophrenia" name="citation_title"/> <meta content="Nadine Dougall" name="citation_author"/> <meta content="University of Stirling" name="citation_author_institution"/> <meta content="Nadine.dougall@stir.ac.uk" name="citation_author_email"/> <meta content="Nicola Maayan" name="citation_author"/> <meta content="Enhance Reviews Ltd" name="citation_author_institution"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Enhance Reviews Ltd" name="citation_author_institution"/> <meta content="Lisa M McDermott" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Andrew McIntosh" name="citation_author"/> <meta content="University of Edinburgh, Royal Edinburgh Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD006081.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/08/20" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006081.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006081.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006081.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [therapeutic use]; Hallucinations [therapy]; Headache; Randomized Controlled Trials as Topic; Schizophrenia [*therapy]; Transcranial Magnetic Stimulation [adverse effects, *methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006081.pub2&amp;doi=10.1002/14651858.CD006081.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="qy4lqFNF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006081\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006081\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","pt","ja","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006081.pub2",title:"Transcranial magnetic stimulation (TMS) for schizophrenia",firstPublishedDate:"Aug 20, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006081.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006081.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006081.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006081.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006081.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006081.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006081.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006081.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006081.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006081.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7118 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006081.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0220"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0109"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-sec-0205"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/appendices#CD006081-sec-0236"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/table_n/CD006081StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/table_n/CD006081StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Transcranial magnetic stimulation (TMS) for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#CD006081-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Nadine Dougall</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#CD006081-cr-0003">Nicola Maayan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#CD006081-cr-0004">Karla Soares‐Weiser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#CD006081-cr-0005">Lisa M McDermott</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information#CD006081-cr-0006">Andrew McIntosh</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information/en#CD006081-sec-0244">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 20 August 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006081.pub2">https://doi.org/10.1002/14651858.CD006081.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006081-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006081-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006081-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006081-abs-0002">日本語</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006081-abs-0001" lang="en"> <section id="CD006081-sec-0001"> <h3 class="title" id="CD006081-sec-0001">Background</h3> <p>People with schizophrenia often experience symptoms which fail to fully respond to antipsychotic medication. Transcranial magnetic stimulation (TMS) has been proposed as a new treatment for people with schizophrenia, especially those who experience persistent auditory hallucinations. </p> </section> <section id="CD006081-sec-0002"> <h3 class="title" id="CD006081-sec-0002">Objectives</h3> <p>To estimate the effects of TMS alone, compared with sham TMS or with 'standard management' and any other comparison interventions in reducing psychotic symptoms associated with schizophrenia. </p> </section> <section id="CD006081-sec-0003"> <h3 class="title" id="CD006081-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group Trials Register (June 2006, June 2008, April 2013). This register is compiled by methodical searches of MEDLINE, EMBASE, BIOSIS, CINAHL, Dissertation abstracts, LILACS, PSYNDEX, PsycINFO, RUSSMED, and Sociofile, and is supplemented with handsearching of relevant journals and numerous conference proceedings. </p> </section> <section id="CD006081-sec-0004"> <h3 class="title" id="CD006081-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials recruiting at least five participants and comparing TMS with sham TMS or any other treatment for people with schizophrenia. </p> </section> <section id="CD006081-sec-0005"> <h3 class="title" id="CD006081-sec-0005">Data collection and analysis</h3> <p>We extracted data independently. For dichotomous data we calculated relative risks (RRs) and their 95% confidence intervals (CIs). For continuous data, we calculated mean differences (MD) and 95% CI. We used a fixed‐effect model. We assessed overall quality of the evidence using the GRADE approach. </p> </section> <section id="CD006081-sec-0006"> <h3 class="title" id="CD006081-sec-0006">Main results</h3> <p>We included 41 studies with 1473 participants in the review. We found significant differences in favour of temporoparietal TMS compared to sham TMS for global state measured on the CGI scale (7 RCTs, n = 224, MD ‐0.5, 95% CI ‐0.76 to ‐0.23, <i>very low‐quality evidence</i> ) and positive symptoms measured on the PANSS scale (5 RCTs, n = 127, MD ‐6.09, 95% CI ‐10.95 to ‐1.22, <i>very low‐quality evidence</i> ). Participants experienced significantly more headaches in the temporoparietal TMS group (10 RCTs, n = 392, RR 2.65, 95% CI 1.56 to 4.50, <i>very low‐quality evidence</i> ). However, no more participants left the study early from the TMS group than from the sham group (<i>very low‐quality evidence</i> ). Cognitive state was assessed using 39 different measures, and all were equivocal (<i>very low‐quality evidence</i> )<i>.</i> </p> <p>We included only two trials which compared temporoparietal TMS with standard treatment. In both trials the participants received first‐ and second‐generation antipsychotic medication in both treatment groups, therefore TMS was used an adjunctive therapy to medication. We found no significant differences in the number of participants that showed clinical improvement in global state (1 RCT, n = 100, RR 1.19, 95% CI 0.91 to 1.57) or left the study early (2 RCTs, n = 140, RR 0.33, 95% CI 0.08 to 1.46) (both <i>very low‐quality evidence</i>). No studies reported on global state score, mental state, cognitive state and adverse effects. </p> <p>For prefrontal TMS compared to sham TMS, global state was measured on three different scales, all of which presented equivocal results (<i>very low quality evidence</i> ). We could not pool data for mental state on the PANSS scale due to high heterogeneity. Cognitive state was assessed using 19 different measures, with 15/19 being equivocal (<i>very low‐quality evidence</i> )<i>.</i> Prefrontal TMS caused more headaches (6 RCTs, n = 164, RR 2.77, 95% CI 1.22 to 6.26, <i>very low‐quality evidence</i> ) but there was no difference in the number of participants leaving the study early (<i>very low‐quality evidence</i>). No studies reported data for clinical improvement. </p> <p>We found a significant difference in favour of prefrontal theta burst stimulation TMS compared to sham TMS for mental state on the PANNS scale (3 RCTs, n = 108, MD ‐5.71, 95% CI ‐9.32 to ‐2.10, <i>very low evidence</i> ). We found no difference for clinical improvement, cognitive state, number of headaches, and leaving the study early (<i>very low‐quality evidence</i>). </p> <p>None of the included studies reported satisfaction with care.</p> </section> <section id="CD006081-sec-0007"> <h3 class="title" id="CD006081-sec-0007">Authors' conclusions</h3> <p>Based on this review, there is insufficient evidence to support or refute the use of TMS to treat symptoms of schizophrenia. Although some evidence suggests that TMS, and in particular temporoparietal TMS, may improve certain symptoms (such as auditory hallucinations and positive symptoms of schizophrenia) compared to sham TMS, the results were not robust enough to be unequivocal across the assessment measures used. There was insufficient evidence to suggest any added benefit with TMS used as an adjunctive therapy to antipsychotic medication. </p> <p>The overall quality of evidence was graded as <i>very low</i> due to risk of bias, and this was accompanied by an imprecision in estimates due to the relatively small number of participants in the studies. Thus, consideration is required in improving the quality of trial processes, as well as the quality of reporting of ongoing and future TMS trials, so as to facilitate accurate future judgements in assessing risk of bias. Differences in TMS techniques in relation to stimulation intensity, stimulation length, brain areas stimulated and variations in the design of sham TMS all contributed to the heterogeneity of study findings and limited the interpretation and applicability of the results. In addition, the trials assessed their outcomes with a variety of scales, and usable data were limited. Therefore, to better evaluate the treatment effects of TMS in people with schizophrenia, we favour the use of standardised treatment protocols and outcome measures. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006081-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD006081-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006081-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006081-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006081-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006081-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/pt#CD006081-abs-0007">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006081-abs-0005" lang="en"> <h3>Transcranial magnetic stimulation (TMS) for the treatment of schizophrenia</h3> <p><b>Review Question</b> <br/> Is transcranial magnetic stimulation (TMS) useful in treating people with schizophrenia? </p> <p><b>Background</b> </p> <p>Transcranial magnetic stimulation is a relatively new and sophisticated device‐based therapy. TMS involves the skilful application of a strong magnetic field close to the surface of the scalp. The TMS device delivers strong and very brief magnetic pulses that stimulate the brain and its network of neurons. TMS is a relatively painless and non‐invasive technique that stimulates parts of the brain (the cerebral cortex). Brain activity has been shown to differ in people with schizophrenia compared to other people. </p> <p>People with schizophrenia often experience symptoms, such as hearing voices or seeing things (hallucinations), which fail to fully respond to medication. TMS has been proposed as a new treatment for people with schizophrenia, especially those who experience persistent auditory hallucinations. Antipsychotic medication also often has debilitating side effects, such as weight gain, apathy or lack or drive, and shaking. TMS could be an alternative treatment for people who do not cope well with standard medication. </p> <p><b>Description of Studies</b> </p> <p>A search for trials was run in 2013 and 41 randomised controlled studies are now included in this review. The studies included people diagnosed with schizophrenia and randomised participants to receive either temporoparietal TMS, prefrontal TMS, sham TMS or standard care. </p> <p><b>Results</b> </p> <p>At this time, there is not strong evidence to support the use of TMS to treat schizophrenia. Some very low‐quality evidence appears to tentatively indicate that TMS may improve global state and certain symptoms such as hearing voices, compared to sham TMS. However, the research at present is not robust, consistent and standardised enough to support any firm conclusions about using TMS for schizophrenia. </p> <p>There was no evidence to indicate TMS may improve symptoms of schizophrenia when used alongside the standard treatment of antipsychotic medication. There were also limitations related to differing TMS techniques. It was difficult to compare the results of studies in this review, as there were various different TMS procedures used, different symptom measures of schizophrenia, and data were limited. More robust and consistent research is therefore required. The authors of the review suggest that in the future, with more research, there is the possibility that TMS may be useful for treating some of the symptoms of schizophrenia. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006081-sec-0220" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-sec-0220">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-sec-0301">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006081-sec-0220"></div> <h3 class="title" id="CD006081-sec-0221">Implications for practice</h3> <section id="CD006081-sec-0221"> <section id="CD006081-sec-0222"> <h5 class="title">1. For people with schizophrenia</h5> <p>At present there is not strong evidence to support the use of TMS (temporoparietal or prefrontal) to treat or manage symptoms of schizophrenia. There was some evidence that TMS may help reduce some symptoms (such as auditory hallucinations and negative symptoms, which include apathy), compared to sham TMS, although the results were unclear and the findings were not the same across all of the small studies identified in the review. Moreover, very few studies compared TMS with standard treatments, including antipsychotic drugs such as clozapine that are often used when troublesome symptoms persist. However, in the future once more high‐quality studies have been conducted, there is a possibility that TMS may be useful for treating and managing some symptoms of schizophrenia in addition to usual care. </p> </section> <section id="CD006081-sec-0223"> <h5 class="title">2. For clinicians</h5> <p>Based on this review, we can make no recommendations for the use of TMS to treat symptoms of schizophrenia. The review found that temporoparietal TMS may help reduce auditory hallucinations and positive symptoms of schizophrenia, and that prefrontal TMS helps to reduce some negative symptoms of schizophrenia. However, any significant results were not consistent across various symptom measures, and there were a limited number of studies for each finding. Although the evidence does not support the use of TMS as a treatment option at present, further research with consistent protocols may lead to the development of an effective procedure for its use in future practice. </p> </section> <section id="CD006081-sec-0224"> <h5 class="title">3. For managers/policy makers</h5> <p>Findings from this review do not provide robust data to support the use of TMS in clinical practice for schizophrenia. However there was a suggestion that TMS may improve some symptoms of schizophrenia, although this was equivocal. Future research that uses routine protocols for both TMS and sham treatment procedures should therefore be supported where possible. </p> </section> </section> <h3 class="title" id="CD006081-sec-0225">Implications for research</h3> <section id="CD006081-sec-0225"> <section id="CD006081-sec-0226"> <h5 class="title">1. General</h5> <p>There are 18 studies currently ongoing, which plan to include 790 participants, and all but one compare TMS to sham TMS. Future studies should aim to adhere to more standardised procedures for both TMS and sham protocols. However, given the range of procedures in the included and ongoing studies, it appears that we are still at an exploratory stage and no clear evidence‐based protocol has emerged. Research should aim for the use of standardised outcomes and measures with which to analyse findings, with publication of analysis protocols before completion of the study itself. This would improve comparability of results across studies and provide a clearer insight into the potential benefits of TMS. </p> </section> <section id="CD006081-sec-0227"> <h5 class="title">2. Specific</h5> <section id="CD006081-sec-0228"> <h6 class="title">2.1 More studies</h6> <p>In order to clarify some of the findings presented in this review, we require further research to investigate the possibility of TMS as a viable treatment option for schizophrenia. Research should specifically aim to identify which symptoms would benefit from the technique and which methods could be most effective. This will need both more high‐quality studies and the recruitment of samples with sufficient statistical power to address the primary questions posed by the research teams. </p> </section> <section id="CD006081-sec-0229"> <h6 class="title">2.2 Duration</h6> <p>There should be standardised procedures in terms of study duration in order to improve compatibility of findings. Although we acknowledge that there are difficulties about adherence for the participant group, research should aim to be more consistent to allow a greater basis for comparison and to extend the clinical data collection period beyond the duration of the treatment phase itself, so as to assess the sustainability of any observed effect. </p> </section> <section id="CD006081-sec-0230"> <h6 class="title">2.3 Sham protocol</h6> <p>The protocol for sham treatment should be standardised to reduce variation and ensure that the control condition refers to a similar procedure across research. Efforts should be made to ensure that the experience of the treatment procedure using the sham protocol is indistinguishable from the active intervention, to improve blinding of participants and their carers. </p> </section> <section id="CD006081-sec-0231"> <h6 class="title">2.4 Intervention protocol</h6> <p>For both temporoparietal and prefrontal TMS, a consistent protocol in relation to stimulation intensity, length of stimulation, and location of treatment should be developed. This would reduce the large variation in procedures and greatly improve the comparability of findings. </p> </section> <section id="CD006081-sec-0232"> <h6 class="title">2.5 Randomisation</h6> <p>There should be clear reporting of study design, in particular the methods to guarantee allocation concealment and double‐blinding, to provide comprehensive information on study procedures which can be compared. There should be good‐quality blinding at allocation, to reduce any risk of selection bias. </p> </section> <section id="CD006081-sec-0233"> <h6 class="title">2.6 Outcome measures</h6> <p>Research should aim to provide consistency of outcome measures for both the type of measure (e.g. endpoint or change score) and the scales used. Comparison of findings is greatly hindered by differences in outcome measures, and consistency in this area would provide a stronger basis for informed conclusions. </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006081-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006081-sec-0029"></div> <div class="table" id="CD006081-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> TEMPOROPARIETAL TMS<br/> <b>Comparison:</b> SHAM TMS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SHAM TMS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TEMPOROPARIETAL TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> <br/> CGI<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7</b> <br/> (0.38 to 128.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> very <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> <br/> CGI<br/> Follow‐up: after treatment to 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean scores for the sham TMS group ranged from 2.4 to 5.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global state score in the intervention groups was<br/> <b>0.5 lower</b> <br/> (0.76 to 0.23 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> PANSS<br/> Follow‐up: after treatment to 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state scores in the sham TMS group ranged from 63.92 to 85.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>6.09 lower</b> <br/> (10.95 to 1.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> <br/> Various measures<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state was reported in 3 studies using 39 different measures. Results were equivocal for all measures </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> <br/> Follow‐up: after treatment to 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were more headaches and jaw and facial contraction in the TMS group. Results for other adverse events ‐ concentration problems, earache, lightheadedness, mild amnesia, restless legs, somatic discomfort, tingling sensation in the arm, worsening hallucinations ‐ were equivocal </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> <br/> (70 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/> (0.46 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>low</b><sup>5,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies for pooled data and the control group risk for single studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ this study had an unclear risk of bias for randomisation, allocation concealment, blinding and incomplete outcome data. Downgraded one level.<br/> <sup>2</sup>Imprecision: very serious ‐ there were very few participants and very few events; there are wide confidence intervals that include both appreciable benefit and appreciable harm. Downgraded two levels<br/> <sup>3</sup>Risk of bias: very serious ‐ five studies had an unclear risk of bias for randomisation, six for allocation concealment, four studies for blinding of participants and four blinding of outcome assessors. One study had a high risk of bias for incomplete outcome data. Downgraded two levels.<br/> <sup>4</sup>Risk of bias: serious ‐ four studies had an unclear risk of bias for randomisation, five for allocation concealment, four for blinding of participants and two for blinding of outcome assessors. Three studies also had an unclear risk for incomplete outcome data. Downgraded one level.<br/> <sup>5</sup>Imprecision: serious ‐ there are wide confidence intervals for this outcome that include appreciable and non‐appreciable benefit. Downgraded one level.<br/> <sup>6</sup>Imprecision: very serious ‐ different scales were used to measure this outcome, all had wide confidence intervals. Downgraded two levels.<br/> <sup>7</sup>Risk of bias: serious ‐ six studies had an unclear risk of bias for randomisation and nine for allocation concealment. All studies had an unclear risk of bias for blinding of participants and three for blinding of outcome assessors. Six studies also had an unclear risk for incomplete outcome data. Downgraded one level.<br/> <sup>8</sup>Risk of bias: serious ‐ six studies had an unclear risk of bias for randomisation, five for allocation concealment, five studies for blinding of participants and four for blinding of outcome assessment. One study had a high risk of bias for incomplete outcome data. Downgraded one level.<br/> <sup>9</sup>Imprecision: very serious ‐ there are wide confidence intervals for this outcome that include appreciable benefit and appreciable harm. Downgraded two levels. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006081-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> TEMPOROPARIETAL TMS<sup>1</sup> <br/> <b>Comparison:</b> STANDARD TREATMENT<sup>1</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> STANDARD TREATMENT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TEMPOROPARIETAL TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> <br/> CGI<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>620 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>738 per 1000</b> <br/> (564 to 973) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.91 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (7 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/> (0.08 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk is</b> the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Participants received first and second generation antipsychotics in both treatment groups<br/> <sup>2</sup>Risk of bias: serious ‐ this study had an unclear risk of bias for allocation concealment and blinding of participants and outcome assessors<br/> <sup>3</sup>Imprecision: serious ‐ the confidence intervals are wide and include both benefit and harm<br/> <sup>4</sup>Risk of bias: serious ‐ one study had an unclear risk of bias for randomisation and both studies for allocation concealment. One study had a unclear risk of bias for blinding of participants<br/> <sup>5</sup>Imprecision: very serious ‐ there were few participants and very few events; there are wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006081-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">PREFRONTAL TMS compared to SHAM TMS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PREFRONTAL TMS compared to SHAM TMS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> PREFRONTAL TMS<br/> <b>Comparison:</b> SHAM TMS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SHAM TMS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PREFRONTAL TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> <br/> Various scales<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 small studies measured global state on the CGI, CGI‐S, GAF and SCL‐90, none of which showed a significant treatment effect </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> PANSS<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was very high heterogeneity for this outcome, so we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> <br/> Various measures<br/> Follow‐up: after treatment to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state was reported in 4 studies using 19 different measures. Results were equivocal for all measures apart from 4 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were more headaches and TMS‐related site discomfort or pain in the TMS group. Results for other adverse effects ‐ cognitive difficulties, facial twitching, worsening of pre‐existing akathisia and OCD ‐ were equivocal </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> <br/> Follow‐up: after treatment to 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> <br/> (59 to 265) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.56 to 2.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ two studies had an unclear risk of bias for randomisation and five for allocation concealment. Five studies had an unclear risk for blinding of participants and two for blinding of outcome assessors and incomplete outcome data.<br/> <sup>2</sup>Incosistency: very serious ‐ there was a very high heterogeneity for this outcome and we did not pool results<br/> <sup>3</sup>Risk of bias: serious ‐ two studies had an unclear risk of bias for randomisation and three for allocation concealment. All studies had an unclear risk for blinding of participants and two studies had an unclear risk for incomplete outcome data<br/> <sup>4</sup>Imprecision: serious ‐ different scales were used to measure this outcome, the majority had wide confidence intervals<br/> <sup>5</sup>Risk of bias: very serious ‐ five studies had an unclear risk of bias for randomisation and allocation concealment. All had an unclear risk for blinding of participants, and two for blinding of outcome assessors. Four had an unclear risk for incomplete outcome data<br/> <sup>6</sup>Imprecision: serious: there are wide confidence intervals<br/> <sup>7</sup>Risk of bias: serious ‐ seven studies had an unclear risk of bias for randomisation and five for allocation concealment. All had an unclear risk for blinding of participants, and three were unclear for blinding of outcome assessors. Four had a high or unclear risk for incomplete outcome data </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006081-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> PREFRONTAL TBS TMS<br/> <b>Comparison:</b> SHAM TMS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SHAM TMS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PREFRONTAL TBS TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.06</b> <br/> (0.21 to 77.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> PANSS<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean scores for the sham TMS group ranged from 67.6 to 68.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>5.71 lower</b> <br/> (9.32 to 2.1 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> <br/> Various measures<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was measured on 2 scale, both showed equivocal results</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No differences in headaches and sleep disorders</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (10 to 242) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> <br/> (0.07 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ there was an unclear risk of bias for allocation concealment and blinding<br/> <sup>2</sup>Imprecision: serious ‐ there were very few participants and very few events; the confidence intervals are wide<br/> <sup>3</sup>Imprecision: serious ‐ there are wide confidence intervals<br/> <sup>4</sup>Imprecision: serious ‐ this was measured on two scales by one study, both of which had wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006081-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-sec-0254">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD006081-sec-0030"></div> <section id="CD006081-sec-0031"> <h3 class="title" id="CD006081-sec-0031">Description of the condition</h3> <p>People with schizophrenia typically experience auditory hallucinations (hearing voices) or delusions (false beliefs) during acute episodes. Although several effective treatments are available, many patients have intractable symptoms that do not recover between acute episodes. In addition, motivation and social behaviour may also be adversely affected (negative symptoms). Relatively high numbers of people with schizophrenia have persistent symptoms in spite of apparently adequate drug treatment. In some cases treatment failure is associated with non‐adherence, although it is understood that many people have enduring symptoms in spite of adequate treatment. Transcranial magnetic stimulation (TMS) could prove an alternative treatment for patients who do not cope well with standard medication. </p> </section> <section id="CD006081-sec-0032"> <h3 class="title" id="CD006081-sec-0032">Description of the intervention</h3> <p>Transcranial magnetic stimulation is a relatively new sophisticated device‐based therapy which involves the skilful application of a strong magnetic field close to the surface of the scalp. The procedure is a non‐invasive and relatively painless technique for stimulating the cerebral cortex and altering neuronal function (<a href="./references#CD006081-bbs2-0127" title="ChouinardPA , Van derWerfYD , LeonardG , PausT . Modulating neural networks with transcranial magnetic stimulation applied over the dorsal premotor and primary motor cortices. Journal of Neurophysiology2003;90(2):1071‐83. ">Chouinard 2003</a>). The device uses specifically‐designed insulated wire coils which deliver strong and very brief magnetic pulses, passing from carefully chosen surface landmarks without hindrance into underlying brain regions. The magnetic field then induces small transient electrical currents in the neural circuitry of treated individuals. By varying the intensity, duration and frequency of the magnetic field, the neuronal systems may be excited or inhibited for as long as the current pulses in the coil (<a href="./references#CD006081-bbs2-0123" title="BarkerAT . The history and basic principles of magnetic nerve stimulation. In: Pascual‐LeoneA , DaveyN , RothwellJ , WassermannEM , PuriBK editor(s). Handbook of Transcranial Magnetic Stimulation. 1st Edition. New York: Oxford University Press, 2002:3‐17. ">Barker 2002</a>). </p> </section> <section id="CD006081-sec-0033"> <h3 class="title" id="CD006081-sec-0033">How the intervention might work</h3> <p>Brain activity has been shown to differ in people with schizophrenia compared to the brain activity of people who do not have this condition. Whereas activity in the temporoparietal cortex (TPC) appears to increase in people with schizophrenia experiencing auditory hallucinations (<a href="./references#CD006081-bbs2-0163" title="ShergillSS , BrammerMJ , WilliamsSC , MurrayRM , McGuirePK . Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Archives of General Psychiatry2000;57:1033‐8. ">Shergill 2000</a>), activity in the dorsolateral prefrontal cortex (DLPFC) appears to be reduced in people with schizophrenia (<a href="./references#CD006081-bbs2-0165" title="WeinbergerDR , BermanKF . Prefrontal function in schizophrenia: confounds and controversies. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences1996;351(1346):1495‐503. ">Weinberger 1996</a>). Reduced activity also appears to be correlated with negative symptoms (e.g. decreased motivation and social function) experienced by the patient. It is possible that by normalising activity in these brain regions, auditory hallucinations and negative symptoms would also improve. </p> <p>Transcranial magnetic stimulation has been applied in several trials in two main paradigms: high‐frequency TMS and low‐frequency TMS. Low‐frequency TMS (1 Hz) is typically applied to the left TPC of patients, aiming to decrease brain activity and reduce auditory hallucinations. High‐frequency TMS is applied to left DLPFC in an attempt to increase activity and reduce negative symptoms. Low‐frequency TMS is considered to inhibit cortical activity (<a href="./references#CD006081-bbs2-0126" title="ChenR , ClassenJ , GerloffC , CelnikP , WassermannEM , HallettM , et al. Depression of motor cortex excitability by low‐frequency transcranial magnetic stimulation. Neurology1997;48(5):1398‐403. ">Chen 1997</a>) and high‐frequency TMS generally increases cortical activity in stimulated areas (<a href="./references#CD006081-bbs2-0157" title="Pascual‐LeoneA , TormosJM , KeenanJ , TarazonaF , CaneteC , CatalaMD . Study and modulation of human cortical excitability with transcranial magnetic stimulation. Journal of Clinical Neurophysiology1998;15(4):333‐4. ">Pascual‐Leone 1998</a>). Positive (<a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>) and negative (<a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>) controlled studies have been published using both treatment approaches, and it is unclear whether TMS represents a significant treatment advance. </p> <p>In schizophrenia, there is evidence of both decreased and increased cortical activity compared to unaffected controls, and in some cases the altered activity correlates with the presence of a known symptom of cognitive deficit. Studies have demonstrated an association between temporal lobe activity and auditory hallucinations in people with schizophrenia (<a href="./references#CD006081-bbs2-0052" title="D'AlfonsoAA , AlemanA , KesselsRP , SchoutenEA , PostmaA , Van derLindenJA , et al. Transcranial magnetic stimulation of left auditory cortex in patients with schizophrenia: effects on hallucinations and neurocognition. Journal of Neuropsychiatry and Clinical Neuroscience2002;14(1):77‐9. ">D'Alfonso 2002</a>; <a href="./references#CD006081-bbs2-0065" title="HoffmanR , BoutrosN , PredaA , RachidF , KrystalJ . One hertz repetitive transcranial magnetic stimulation reduces auditory hallucinations in patients with schizophrenia. Proceedings of the 7th World Congress of Biological Psychiatry. 2001 Jul 1‐6; Berlin, Germany. HoffmanRE , BoutrosNN , HuS , BermanRM , KrystalJH , Charney‐DS . Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet2000;355(9209):1073‐5. [MEDLINE: 10744097] ">Hoffman 2000</a>; <a href="./references#CD006081-bbs2-0020" title="LeeS‐H , KimW , ChungY‐C , JungK‐H , BahkW‐M , JunT‐Y , et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment‐refractory auditory hallucinations. Neuroscience Letters2005;376(3):177‐81. [MEDLINE: 15721217; EMBASE 2005083871] ">Lee 2005</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>). Active stimulation has been found to significantly reduce hallucinations in comparison to sham stimulation (<a href="./references#CD006081-bbs2-0065" title="HoffmanR , BoutrosN , PredaA , RachidF , KrystalJ . One hertz repetitive transcranial magnetic stimulation reduces auditory hallucinations in patients with schizophrenia. Proceedings of the 7th World Congress of Biological Psychiatry. 2001 Jul 1‐6; Berlin, Germany. HoffmanRE , BoutrosNN , HuS , BermanRM , KrystalJH , Charney‐DS . Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet2000;355(9209):1073‐5. [MEDLINE: 10744097] ">Hoffman 2000</a>). Not all attempts at replication have unequivocally supported Hoffman's findings (<a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0160" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , StamatiadisL , VicautE , LipskiH , JanuelD . Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: A double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006b</a>). </p> </section> <section id="CD006081-sec-0034"> <h3 class="title" id="CD006081-sec-0034">Why it is important to do this review</h3> <p>Placebo arms of TMS trials often use sham treatments. There are limitations to this approach; no satisfactory placebo condition has been established and individuals may not have identical expectations of real or sham TMS. Placebo or sham TMS should result in scalp and noise sensation identical to active TMS, without the cortical stimulation. Although noise sensation can be mimicked, generating the scalp sensation may also produce a therapeutic cortical stimulation. Avoiding the confounding of cortical stimulation with sham TMS yields a control arm of the trial which typically controls for noise sensation but not for scalp sensation. In trials which implement sham TMS, double‐blinding of observer and participant is not guaranteed and estimated efficacy rates of TMS will possibly be confounded if participants are aware which treatment arm they are in. </p> <p>Bearing in mind the limitations of the trial methodology and in the absence of an entirely inactive sham condition that mimics real TMS, this systematic review aims to evaluate the current evidence base of TMS in the treatment for schizophrenia. We wish to ascertain the efficacy and safety of TMS, explore sources of heterogeneity that might explain contradictory positive and negative effects, investigate whether pooled effect sizes can be derived and whether they are statistically robust, and lastly, provide recommendations where possible for future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006081-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-sec-0259">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006081-sec-0035"></div> <p>To estimate the effects of TMS alone compared with sham TMS or with 'standard management' and any other comparison interventions in reducing psychotic symptoms associated with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006081-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-sec-0260">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006081-sec-0036"></div> <section id="CD006081-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006081-sec-0038"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials with group sizes of at least five. Where a trial was described as 'double‐blind' but it implied that the study is randomised and the demographic details of each group are similar, we included it. We excluded quasi‐randomised studies, such as those allocated by using alternate days of the week. </p> </section> <section id="CD006081-sec-0039"> <h4 class="title">Types of participants</h4> <p>People with schizophrenia and related affective psychoses, diagnosed according to standardised operational criteria, irrespective of age and sex. </p> </section> <section id="CD006081-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD006081-sec-0041"> <h5 class="title">1. Transcranial magnetic stimulation: at any stimulus voltage, frequency or charge, administered to the head at any location </h5> </section> <section id="CD006081-sec-0042"> <h5 class="title">2. Sham TMS: TMS administered using fake instruments or with the coil applied at an oblique angle, greater than or equal to 45 degrees, to the skull </h5> </section> <section id="CD006081-sec-0043"> <h5 class="title">3. Standard treatment: any treatment (including antipsychotic medication) provided as part of routine care, however defined </h5> </section> <section id="CD006081-sec-0044"> <h5 class="title">4. Any other pharmacological or non‐pharmacological treatments given as part of an experimental intervention. Examples might include electroconvulsive therapy (ECT) and cognitive behaviour therapy (CBT). </h5> </section> </section> <section id="CD006081-sec-0045"> <h4 class="title">Types of outcome measures</h4> <p>We classified outcomes in the eight categories detailed below:</p> <section id="CD006081-sec-0046"> <h5 class="title">Primary outcomes</h5> <section id="CD006081-sec-0047"> <h6 class="title">1. Global state</h6> <p>1.1 Clinical improvement in global state (as defined by individual studies)<br/> 1.2 Mean endpoint global state score<br/> 1.3 Mean change in global state scores </p> </section> </section> <section id="CD006081-sec-0048"> <h5 class="title">Secondary outcomes</h5> <section id="CD006081-sec-0049"> <h6 class="title">2. Mental state</h6> <p>2.1 Clinical improvement in general mental state (as defined by individual studies)<br/> 2.2 Mean endpoint general mental state score<br/> 2.3 Mean change in general mental state scores<br/> 2.4 No clinically important change in specific symptoms<br/> 2.5 Mean endpoint‐specific symptom score<br/> 2.6 Mean change in specific symptom scores </p> </section> <section id="CD006081-sec-0050"> <h6 class="title">3. Cognitive state</h6> <p>3.1 Clinical improvement in cognitive state (as defined by individual studies)<br/> 3.2 Mean endpoint cognitive state score<br/> 3.3 Mean change in cognitive state scores<br/> 3.4 Mean endpoint‐specific cognitive state score<br/> 3.5 Mean change in specific cognitive state scores </p> </section> <section id="CD006081-sec-0051"> <h6 class="title">4. Adverse effects</h6> <p>4.1 Incidence of adverse effects, general or specific<br/> 4.2 Leaving the study early<br/> 4.3 Measured acceptance of treatment<br/> 4.4 Use of antiparkinsonian treatment<br/> 4.5 Sudden and unexpected death </p> </section> <section id="CD006081-sec-0052"> <h6 class="title">5. Hospital and service outcomes</h6> <p>5.1 Hospitalisation of people in the community<br/> 5.2 Duration of hospital stay<br/> 5.3 Severity of symptoms when discharged from hospital<br/> 5.4 Changes in hospital status (for example, changes from informal care to formal detention in care, changes of level of observation by ward staff and use of secluded nursing environment)<br/> 5.5 Changes in services provided by community teams </p> </section> <section id="CD006081-sec-0053"> <h6 class="title">6. Satisfaction with care</h6> <p>6.1 Recipient of care<br/> 6.2 Informal care givers<br/> 6.3 Professional carers </p> </section> <section id="CD006081-sec-0054"> <h6 class="title">7. Economic outcomes</h6> </section> <section id="CD006081-sec-0055"> <h6 class="title">8. Quality of Life</h6> <p>8.1 Clinical improvement in quality of life (as defined by individual studies)<br/> 8.2 Mean endpoint quality of life score<br/> 8.3 Mean change in quality of life scores </p> </section> <section id="CD006081-sec-0056"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD006081-bbs2-0162" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Chichester: John Wiley &amp; Son. ">Schünemann 2008</a>) and used <a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADE</a> profiler to import data from <a href="http://www.ims.cochrane.org/revman" target="_blank">Review Manager 5</a> (RevMan) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to participant care and decision making. We included the following short‐ or medium‐term outcomes in 'Summary of findings' tables: </p> </section> <section id="CD006081-sec-0057"> <h6 class="title">1. Global state</h6> <p>1.1 Clinical improvement in global state<br/> 1.2 Mean endpoint score </p> </section> <section id="CD006081-sec-0058"> <h6 class="title">2. Mental state</h6> <p>2.1 Mean endpoint score</p> </section> <section id="CD006081-sec-0059"> <h6 class="title">3. Cognitive state</h6> <p>3.1 Mean change score</p> </section> <section id="CD006081-sec-0060"> <h6 class="title">4. Adverse effects</h6> <p>4.1 Incidence of adverse effects, general or specific<br/> 4.2 Leaving the study early </p> </section> <section id="CD006081-sec-0061"> <h6 class="title">5. Satisfaction with care</h6> <p>5.1 Recipient of care</p> </section> </section> </section> </section> <section id="CD006081-sec-0062"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006081-sec-0063"> <h4 class="title">Electronic searches</h4> <section id="CD006081-sec-0064"> <h5 class="title">1. The Cochrane Schizophrenia Group's Trials Register</h5> <p>We searched this in June 2006, June 2008 and April 2013 using the phrase:</p> <p>[((*TMS* OR *transcranial* OR *trans‐cranial* OR *magnetic *) in REFERENCE) and (magn* in STUDY)] </p> <p>This register is compiled by systematic searches of major databases, handsearches and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group Module</a>). </p> <p>We applied no language restriction for the searching.</p> </section> <section id="CD006081-sec-0065"> <h5 class="title">2. Requests for additional data</h5> <p>We contacted Magstim Company Ltd., the company who markets TMS machines in the UK, for published and unpublished data on the treatment (<a href="#CD006081-tbl-0005">Table 1</a>). </p> <div class="table" id="CD006081-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Magstim Company Limited</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Contact details</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mr John H Starzewski<br/> Managing Director<br/> Magstim Limited<br/> Spring Gardens<br/> Whitland SA34 0HR<br/> UK<br/> <br/> Telephone: +44 1994 241093<br/> URL: http://www.magstim.com/index.html </p> </td> </tr> </tbody> </table> </div> </section> </section> <section id="CD006081-sec-0066"> <h4 class="title">Searching other resources</h4> <section id="CD006081-sec-0067"> <h5 class="title">1. Reference lists</h5> <p>We retrospectively searched reference lists of included and excluded studies for additional relevant studies, and contacted authors of relevant studies to enquire about other sources of relevant information. We prospectively searched for studies which cited included relevant studies up to April 2013 </p> </section> </section> </section> <section id="CD006081-sec-0068"> <h3 class="title" id="CD006081-sec-0068">Data collection and analysis</h3> <section id="CD006081-sec-0069"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ND, AM for the 2006 and 2008 searches, and two members of the Enhance Reviews team (NM and KSW) for the 2013 update search) independently inspected all abstracts of studies identified as above and identified potentially relevant reports. Where disagreement occurred we resolved it by discussion, or where there was still doubt, we acquired the full article for further inspection. Jun Xia screened Chinese language studies. We acquired the full articles of relevant reports for reassessment and carefully inspected them for a final decision on inclusion (see <a href="#CD006081-sec-0037">Criteria for considering studies for this review</a>). The review authors were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we added these studies to those awaiting assessment and contacted the authors of the papers for clarification. </p> </section> <section id="CD006081-sec-0070"> <h4 class="title">Data extraction and management</h4> <section id="CD006081-sec-0071"> <h5 class="title">1. Data extraction</h5> <p>Review authors ND and AM extracted data independently from included studies resulting from the 2006 and 2008 searches, and two members of the Enhance Reviews team (NM and KSW) extracted data independently for the included studies from the 2013 search. Again, we discussed any disagreement, documented decisions and, if necessary, contacted authors of studies for clarification. JX extracted data for all Chinese studies. We extracted data presented only in graphs and figures whenever possible, but only included them if two review authors independently had the same result. Where possible, we extracted data relevant to each component centre of multicentre studies separately. </p> </section> <section id="CD006081-sec-0072"> <h5 class="title">2. Management</h5> <section id="CD006081-sec-0073"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard, simple forms.</p> </section> <section id="CD006081-sec-0074"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if: a) the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD006081-bbs2-0152" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. [PUBMED: 8932886] ">Marshall 2000</a>); and b) the measuring instrument is not written or modified by one of the trialists for that particular trial. Ideally the measuring instrument should either be a self report or completed by an independent rater or relative (not the therapist). </p> </section> <section id="CD006081-sec-0075"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data and only use change data if the former were not available. We combined endpoint and change data in the analysis as we used weighted mean differences rather than standardised mean differences throughout (<a href="./references#CD006081-bbs2-0146" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>, chapter 9.4.5.2). All data in the analyses are endpoint data unless specifically noted as change data in the footnote of the analysis. </p> </section> <section id="CD006081-sec-0076"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to all data before inclusion: a) standard deviations (SDs) and means were reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, was less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution, (<a href="./references#CD006081-bbs2-0119" title="AltmanDG , BlandJM . Statistics notes: detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>); c) if a scale started from a positive value (such as the positive and negative syndrome scale (PANSS) which can have values from 30 to 210) we modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2SD &gt; (S ‐ S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and endpoint and these rules can be applied. When continuous data were presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data were skewed or not. We entered skewed data from studies of fewer than 200 participants in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large, and we entered them into syntheses. </p> </section> <section id="CD006081-sec-0077"> <h6 class="title">2.5 Common measure</h6> <p>To facilitate comparison between trials, we intended to convert variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD006081-sec-0078"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we tried to convert outcome measures to dichotomous data. This could be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. We generally assumed that if there had been a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD006081-bbs2-0156" title="OverallJ , GorhamD . The Brief Psychiatric Rating Scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD006081-bbs2-0147" title="KaySR , OplerLA , FiszbeinA . Positive and negative syndrome scale (PANSS) manual . Positive and negative syndrome scale (PANSS) manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), we could consider this as a clinically significant response (<a href="./references#CD006081-bbs2-0148" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD006081-bbs2-0149" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005b</a>). Data based on these thresholds were not available, so we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD006081-sec-0079"> <h6 class="title">2.7 Direction of graphs</h6> <p>We extracted and entered data into RevMan in such a way that the area to the left of the line of no effect indicated a 'favourable' outcome for TMS. For some outcomes this was not possible, and we reported data where the left of the line indicates an unfavourable outcome. We have noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD006081-sec-0080"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>ND and AM independently allocated trials from the 2006 and 2008 searches to Categories A or B in the review. When upgraded criteria for risk of bias became available, LMcD correspondingly upgraded the trial quality assessments using criteria described in the Cochrane Handbook (<a href="./references#CD006081-bbs2-0146" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). Two members of the Enhance Reviews team assessed the risk of bias of studies included from the 2013 search, also using the upgraded criteria. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. When the raters disagreed, they made the final rating by consensus, with the involvement of another member of the review team. When there were inadequate details of randomisation and other characteristics of trials, we contacted authors of the studies in order to obtain further information. We reported non‐concurrence in quality assessment, but if disputes arose as to the appropriate category to which a trial should be allocated, we resolved the matter by discussion. We noted the level of risk of bias in both the text of the review and in the 'Summary of findings' tables. </p> </section> <section id="CD006081-sec-0081"> <h4 class="title">Measures of treatment effect</h4> <section id="CD006081-sec-0082"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that the RR is more intuitive (<a href="./references#CD006081-bbs2-0125" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>) than the odds ratios and that odds ratios tend to be interpreted as RRs by clinicians (<a href="./references#CD006081-bbs2-0128" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. 2000. ">Deeks 2000</a>). </p> </section> <section id="CD006081-sec-0083"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated the mean difference (MD) between groups with 95% CIs. </p> </section> </section> <section id="CD006081-sec-0084"> <h4 class="title">Unit of analysis issues</h4> <section id="CD006081-sec-0085"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data pose problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD006081-bbs2-0131" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>) whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD006081-bbs2-0124" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD006081-bbs2-0140" title="GullifordMC , UkoumunneOC , ChinnS . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>None of the included studies was cluster‐randomised. Measures to deal with cluster RCTs that we would have employed, and that we shall use for updates of this review for such designs, are described in the section <a href="#CD006081-sec-0248">Differences between protocol and review</a>. </p> </section> <section id="CD006081-sec-0086"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. physiological or pharmacological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state, despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD006081-bbs2-0135" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials:methodological issues. International Journal of Epidemiology2002;31(1):140‐9. [PUBMED: 11914310] ">Elbourne 2002</a>). As both effects are very likely in schizophrenia, we only used data from the first phase of cross‐over studies. </p> </section> <section id="CD006081-sec-0087"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>When a study involved more than two treatment arms, if relevant, we presented the additional treatment arms in comparisons. If data were binary these were simply added and combined within the two‐by‐two table. If data were continuous, we combined data using the RevMan calculator. Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD006081-sec-0088"> <h4 class="title">Dealing with missing data</h4> <section id="CD006081-sec-0089"> <h5 class="title">1. Overall loss of credibility</h5> <p>To some degree, loss of follow‐up data must lose credibility (<a href="./references#CD006081-bbs2-0166" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We choose that, for any particular outcome, if more than 50% of data were unaccounted for, we did not reproduce these data or use them within analyses. If more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we would have flagged such data with an asterisk (*) to indicate that such a result may well be prone to bias. </p> </section> <section id="CD006081-sec-0090"> <h5 class="title">2. Binary</h5> <p>All analyses have been conducted per number analysed in the studies. For the primary outcome 'clinical improvement in global state', if there was attrition, we compared in sensitivity analyses the results per number analysed with results of all the participants randomised (an intention‐to‐treat analysis). For the intention‐to‐treat analysis, we assumed that those leaving the study early all have the same rates of negative outcome as those who completed the trial. </p> </section> <section id="CD006081-sec-0091"> <h5 class="title">3. Continuous</h5> <section id="CD006081-sec-0092"> <h6 class="title">3.1 Attrition</h6> <p>In the case where attrition for a continuous outcome is between 0 and 50% and completer‐only data were reported, we have reproduced these. </p> </section> <section id="CD006081-sec-0093"> <h6 class="title">3.2 Standard deviations</h6> <p>We first tried to obtain the missing values from the authors. When these were not available, we did not add the data to the analysis. </p> <p>Measures to deal with missing SDs that we shall use for updates of this review are described in the section <a href="#CD006081-sec-0248">Differences between protocol and review</a>. </p> </section> <section id="CD006081-sec-0094"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would be employed within the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD006081-bbs2-0150" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). Therefore, where LOCF data had been used in the trial, if less than 50% of the data had been assumed, we reproduced these data and indicated that they are the product of LOCF assumptions. </p> </section> </section> </section> <section id="CD006081-sec-0095"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD006081-sec-0096"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying situations or people which we had not predicted would arise. When such situations or participant groups arose, we discussed them fully. </p> </section> <section id="CD006081-sec-0097"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we discussed them fully. </p> </section> <section id="CD006081-sec-0098"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD006081-sec-0099"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD006081-sec-0100"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD006081-bbs2-0144" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed value of I² depends on: a) magnitude and direction of effects, and b) strength of evidence for heterogeneity (e.g. P value from Chi² test, or a confidence interval for I²). An I² estimate greater than or equal to 50% accompanied by a statistically significant Chi² statistic, we interpreted as possibly evidence of substantial levels of heterogeneity (Section 9.5.2 ‐ <a href="./references#CD006081-bbs2-0129" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. in: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). When we found substantial levels of heterogeneity in the primary outcome measure, we cautiously explored reasons for heterogeneity (<a href="#CD006081-sec-0103">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD006081-sec-0101"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD006081-bbs2-0134" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). These are described in Chapter 8 of the Cochrane Handbook (<a href="./references#CD006081-bbs2-0145" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). We are aware that funnel plots may be useful in investigating reporting biases, but are of limited power to detect small‐study effects. We did not use funnel plots for any outcomes as there were 10 or fewer studies, or where all studies were of similar sizes; in the case of the adverse effect headache, we did not produce a funnel plot, as this outcome was not systematically reported by all studies. Had we used funnel plots, we would have sought statistical advice in their interpretation. </p> </section> <section id="CD006081-sec-0102"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference use of fixed‐effect or random‐effects models. The fixed‐effect model assumes each trial makes an estimate of a common effect size of the same population. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. The random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model. It puts added weight onto small studies, which are often the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. For this reason we favoured using fixed‐effect models, employing random‐effects only when investigating heterogeneity. </p> </section> <section id="CD006081-sec-0103"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD006081-sec-0104"> <h5 class="title">1. Subgroup analysis</h5> <p>We planned no subgroup analyses for this review. We knew the literature would yield sparse amounts of data and that any subgroup analysis would most likely be inadequately powered for us to draw any conclusions. </p> </section> <section id="CD006081-sec-0105"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>If inconsistency was high, we reported it. First we investigated whether data had been entered correctly. Second, where data were correct, we visually inspected the graph, and successively removed outlying studies, to see if heterogeneity remained. For this review, we decided that should this occur with data contributing to the summary finding no more than around 10% of the total weighting, we would present the data. If not, we did not pool data, but discussed the issues. We know of no supporting research for this 10% cut‐off but are investigating the use of prediction intervals as an alternative to this unsatisfactory state. When unanticipated clinical or methodological heterogeneity was obvious, we simply stated hypotheses regarding these for future reviews or versions of this review. We did not undertake analyses relating to these. </p> </section> </section> <section id="CD006081-sec-0106"> <h4 class="title">Sensitivity analysis</h4> <section id="CD006081-sec-0107"> <h5 class="title">1. Implication of randomisation</h5> <p>We planned to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. All studies were reported as randomised, so we did not undertake any sensitivity analysis related to implication of randomisation. </p> </section> <section id="CD006081-sec-0108"> <h5 class="title">2. High attrition rates</h5> <p>We planned a sensitivity analysis to test how prone results were to change when we compared 'completer' data only to the imputed data, using the above assumption. If there had been a substantial difference, we would have reported results and discussed them but continued to employ our assumption. However, we did not make any assumptions about lost binary data and undertook no sensitivity analysis. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006081-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006081-sec-0109"></div> <section id="CD006081-sec-0110"> <h3 class="title">Description of studies</h3> <p>For a full description of studies please see: <a href="./references#CD006081-sec-0250" title="">Characteristics of included studies</a> and <a href="./references#CD006081-sec-0251" title="">Characteristics of excluded studies</a>. </p> <section id="CD006081-sec-0111"> <h4 class="title">Results of the search</h4> <p>The search strategy identified 99 reports that were potentially relevant. Agreement about which reports may have been randomised was 100%. In total, we included 41 studies in the review and in the analysis (see <a href="#CD006081-fig-0001">Figure 1</a>). One study (<a href="./references#CD006081-bbs2-0073" title="JinY , KempAS , HuangY , ThaiTM , LiuZ , XuW , et al. Alpha EEG guided TMS in schizophrenia. Brain Stimulation2012;5(4):560‐8. ">Jin 2012</a>) met the inclusion criteria but did not report data in a usable way, and is in the excluded studies table. </p> <div class="figure" id="CD006081-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006081-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006081-sec-0112"> <h4 class="title">Included studies</h4> <section id="CD006081-sec-0113"> <h5 class="title">1. Length of studies</h5> <p>The duration of trials ranged from four days (<a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>) to 10 weeks (<a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>); 26 trials were short (from five days to two weeks), 12 were medium length (three to six weeks) and four trials were long (eight weeks or longer). </p> </section> <section id="CD006081-sec-0114"> <h5 class="title">2. Design</h5> <p>All but two included studies presented a parallel longitudinal design and two studies had a cross‐over design (<a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>). </p> </section> <section id="CD006081-sec-0115"> <h5 class="title">3. Participants</h5> <p>Most studies included participants with schizophrenia or schizoaffective disorder according to the DSM‐IV. Of those that did not use DSM‐IV, seven studies diagnosed schizophrenia according to the CCMD‐3 (<a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0013" title="高志勤 , 余海鹰 , 崔雪莲 , 邱旭萍 . Low‐frequency repetitive transcranial magnetic stimulation treatment of chronic auditory hallucinations of schizophrenia efficacy soldiers] Google Translate [低频重复经颅磁刺激治疗军人精神分裂症慢性幻听疗效观察 []. People's Military Surgeon [人民军医]2010;53(1):5‐6. ">Gao 2010</a>; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>). <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> diagnosed according to DSM‐IV‐TR. <a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>, <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>, and <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a> used ICD‐10, and <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a> OPCRIT 4.0.<br/> In total, 1473 participants are included in the review, and the number of people included in individual studies ranged from 10 (<a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>) to 100 (<a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>). </p> </section> <section id="CD006081-sec-0116"> <h5 class="title">4. Settings</h5> <p>Eleven studies included inpatients (<a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a>; <a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>; <a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>; <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>; <a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>), five studies included outpatients (<a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>; <a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>) and five studies included both inpatients and outpatients (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a>; <a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a>). In 22 studies the setting was either unclear or not reported. </p> <p>Fourteen studies were carried out in China (<a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a>; <a href="./references#CD006081-bbs2-0013" title="高志勤 , 余海鹰 , 崔雪莲 , 邱旭萍 . Low‐frequency repetitive transcranial magnetic stimulation treatment of chronic auditory hallucinations of schizophrenia efficacy soldiers] Google Translate [低频重复经颅磁刺激治疗军人精神分裂症慢性幻听疗效观察 []. People's Military Surgeon [人民军医]2010;53(1):5‐6. ">Gao 2010</a>; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>; <a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>; <a href="./references#CD006081-bbs2-0030" title="RenY‐P , ZhouD‐F , CaiZ‐J , HuangQ , LuL , ChenQ . Effects of high frequency repetitive transcranial magnetic stimulation on refractory negative symptom of schizophrenia: A double blind, randomized controlled trial. Chinese Mental Health Journal [中国心理卫生杂志]2011;25(2):89‐92. ">Ren 2011</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>; <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>), 13 in Europe, including three in the Czech Republic (<a href="./references#CD006081-bbs2-0019" title="KlirovaM , HoracekJ , NovakT , CermakJ , TislerovaB , TinteraJ . Clinical response of neuronavigated repetitive‐tms in the treatment of auditory hallucinations. European Neuropsychopharmacology2010;1:304‐5. KlirovaM , HorekJ , ErmkJ , NovkT , TilerovB . Clinical response of neuronavigated rtms in the treatment of auditory hallucinations. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal. 2009:S773. ">Klirova 2010</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>), three in France (<a href="./references#CD006081-bbs2-0004" title="BrunelinJ , PouletE , BediouB , KallelL , DaleryJ , D'amatoT , et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. Schizophrenia Research2006;81(1):41‐5. [EMBASE 2005578713] ">Brunelin 2006</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>), two in Germany (<a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a>; <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>), two in the Netherlands (<a href="./references#CD006081-bbs2-0035" title="SlotemaCC , BlomJD , HoekHW , KahnRS , SommerIE . The efficacy of low‐frequency repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations may be low. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. SlotemaCW , BlomJD , DeWeijerAD , DiederenKM , GoekoopR , LooijestijnJ , et al. Can low‐frequency repetitive transcranial magnetic stimulation really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry2011;69(5):450‐6. [MEDLINE: BIOSIS:PREV201100154047] SlotemaCW , BlomJD , HoekHW , KahnRS , SommerIE . Can low‐frequency rtms really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large rct. Schizophrenia Research2010;117(2‐3):534. [MEDLINE: ISI:000276936801402] ">Slotema 2011</a>; <a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a>), two in the UK (<a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>), and one in Finland (<a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>). Of the remainder, six were conducted in the USA (<a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a>; <a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a>) or Canada (<a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a>; <a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>), two in Australia (<a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>), two in Brazil (<a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; <a href="./references#CD006081-bbs2-0031" title="RosaMO , GattazWF , RosaMA , RumiDO , TavaresH , MyczkowskiM , et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. Journal of Clinical Psychiatry2007; Vol. 68, issue 10:1528‐32. ">Rosa 2007</a>), two in Israel (<a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>; <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a>), one in India (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>), and one in Korea (<a href="./references#CD006081-bbs2-0020" title="LeeS‐H , KimW , ChungY‐C , JungK‐H , BahkW‐M , JunT‐Y , et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment‐refractory auditory hallucinations. Neuroscience Letters2005;376(3):177‐81. [MEDLINE: 15721217; EMBASE 2005083871] ">Lee 2005</a>). </p> </section> <section id="CD006081-sec-0117"> <h5 class="title">5. Interventions</h5> <section id="CD006081-sec-0118"> <h6 class="title">5.1 Temporoparietal TMS</h6> <p>Twenty‐two studies used temporoparietal TMS, most using the left temporoparietal region, <a href="./references#CD006081-bbs2-0020" title="LeeS‐H , KimW , ChungY‐C , JungK‐H , BahkW‐M , JunT‐Y , et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment‐refractory auditory hallucinations. Neuroscience Letters2005;376(3):177‐81. [MEDLINE: 15721217; EMBASE 2005083871] ">Lee 2005</a> also using right temporoparietal TMS, and <a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a> using Wernicke's area and right homologous area. Most studies used low‐frequency TMS with 1 Hz at 80 to 110% motor threshold; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a> and <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> both used 10 Hz at 110% motor threshold, <a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a> used 1 Hz at 20% of motor threshold and <a href="./references#CD006081-bbs2-0019" title="KlirovaM , HoracekJ , NovakT , CermakJ , TislerovaB , TinteraJ . Clinical response of neuronavigated repetitive‐tms in the treatment of auditory hallucinations. European Neuropsychopharmacology2010;1:304‐5. KlirovaM , HorekJ , ErmkJ , NovkT , TilerovB . Clinical response of neuronavigated rtms in the treatment of auditory hallucinations. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal. 2009:S773. ">Klirova 2010</a> used 0.9 Hz at 100% motor threshold. <a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a> included two TMS groups, one with priming TMS of 6 Hz at 90% motor threshold. </p> <p>In regards to length of TMS stimulations, a wide variety were reported across studies, ranging from five sessions of one minute, with one minute gaps (<a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>) to 12 sessions of 20 minutes each a day (<a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a>). <a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a> used MRI‐targeted TMS, and <a href="./references#CD006081-bbs2-0019" title="KlirovaM , HoracekJ , NovakT , CermakJ , TislerovaB , TinteraJ . Clinical response of neuronavigated repetitive‐tms in the treatment of auditory hallucinations. European Neuropsychopharmacology2010;1:304‐5. KlirovaM , HorekJ , ErmkJ , NovkT , TilerovB . Clinical response of neuronavigated rtms in the treatment of auditory hallucinations. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal. 2009:S773. ">Klirova 2010</a> and <a href="./references#CD006081-bbs2-0035" title="SlotemaCC , BlomJD , HoekHW , KahnRS , SommerIE . The efficacy of low‐frequency repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations may be low. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. SlotemaCW , BlomJD , DeWeijerAD , DiederenKM , GoekoopR , LooijestijnJ , et al. Can low‐frequency repetitive transcranial magnetic stimulation really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry2011;69(5):450‐6. [MEDLINE: BIOSIS:PREV201100154047] SlotemaCW , BlomJD , HoekHW , KahnRS , SommerIE . Can low‐frequency rtms really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large rct. Schizophrenia Research2010;117(2‐3):534. [MEDLINE: ISI:000276936801402] ">Slotema 2011</a> both included an MRI‐targeted TMS arm and a non‐targeted TMS arm. <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>, <a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>, and <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a> reported using the 10 ‐ 20 EEG electrode position system. <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> used deep H1 coil TMS with single pulse stimulation, which allows stimulation of deeper brain areas. </p> </section> <section id="CD006081-sec-0119"> <h6 class="title">5.2 Prefrontal TMS</h6> <p>Nineteen studies used prefrontal TMS, with most using left prefrontal TMS or left dorsolateral prefrontal cortex TMS. <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a> reported using right prefrontal TMS and <a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>; <a href="./references#CD006081-bbs2-0030" title="RenY‐P , ZhouD‐F , CaiZ‐J , HuangQ , LuL , ChenQ . Effects of high frequency repetitive transcranial magnetic stimulation on refractory negative symptom of schizophrenia: A double blind, randomized controlled trial. Chinese Mental Health Journal [中国心理卫生杂志]2011;25(2):89‐92. ">Ren 2011</a> and <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a> reported using bilateral prefrontal TMS. Various stimulations of TMS were administered. Seven studies reported using 10 Hz at 90 to 110% motor threshold, <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a> used 15 Hz at 90% motor threshold, three studies used 20 Hz at 90% motor threshold (<a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>). Klein used low‐frequency TMS with 1 Hz at 10% above threshold. Two studies (<a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>) used theta burst stimulation (TBS) TMS, in which 50 Hz are applied in bursts, and <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a> used three arms of TMS 10 Hz, 20 Hz and TBS (50 Hz). </p> <p>In terms of stimulation length for each session of TMS, there was much variation reported across the studies. TMS ranged from two trains of one minute with a three‐minute gap (<a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>), to 40 trains of 2.5 seconds with a 30‐second gap (<a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>). <a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a> used MRI‐targeted TMS and <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> and <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a> reported using the 10 ‐ 20 EEG electrode position system. </p> </section> <section id="CD006081-sec-0120"> <h6 class="title">5.3 Sham TMS</h6> <p>For the sham TMS condition a variety of techniques were used. Seventeen studies described using the same stimulation as for active TMS but with the edge resting at a 90 degree angle to the scalp, six studies used a 45 degree angle (<a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; <a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a>; <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>) and two at 180 degrees (<a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>, <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>). <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a> and <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a> used the reverse side of the coil plane to the scalp. <a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a> used placebo stimulation, which feels similar to real rTMS but does not produce direct brain effects, <a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a> used sham designed to produce an identical sound, <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a> administered sham in the single‐wing tilt position. Additionally, some studies described further sham methods which included using the same stimulation as for active TMS but with a sham coil designed to produce identical sound (<a href="./references#CD006081-bbs2-0004" title="BrunelinJ , PouletE , BediouB , KallelL , DaleryJ , D'amatoT , et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. Schizophrenia Research2006;81(1):41‐5. [EMBASE 2005578713] ">Brunelin 2006</a>; <a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0031" title="RosaMO , GattazWF , RosaMA , RumiDO , TavaresH , MyczkowskiM , et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. Journal of Clinical Psychiatry2007; Vol. 68, issue 10:1528‐32. ">Rosa 2007</a>; <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a>; <a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>), and a sham treatment which used a magnetically non‐translucent headpiece (<a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a>). <a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a> and <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> did not use sham but compared TMS to antipsychotics only. </p> </section> <section id="CD006081-sec-0121"> <h6 class="title">5.4 Standard treatment</h6> <p>Two studies (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>) compared temporoparietal TMS to standard treatment, which was treatment with antipsychotics. In both trials, participants in the TMS group also received antipsychotics. We found no studies that compared prefrontal TMS to standard treatment. </p> </section> </section> <section id="CD006081-sec-0122"> <h5 class="title">6. Use of antipsychotics</h5> <p>In 10 studies participants in both treatment groups received first‐generation and second‐generation antipsychotics (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a>; <a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a>; <a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>; <a href="./references#CD006081-bbs2-0030" title="RenY‐P , ZhouD‐F , CaiZ‐J , HuangQ , LuL , ChenQ . Effects of high frequency repetitive transcranial magnetic stimulation on refractory negative symptom of schizophrenia: A double blind, randomized controlled trial. Chinese Mental Health Journal [中国心理卫生杂志]2011;25(2):89‐92. ">Ren 2011</a>; <a href="./references#CD006081-bbs2-0035" title="SlotemaCC , BlomJD , HoekHW , KahnRS , SommerIE . The efficacy of low‐frequency repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations may be low. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. SlotemaCW , BlomJD , DeWeijerAD , DiederenKM , GoekoopR , LooijestijnJ , et al. Can low‐frequency repetitive transcranial magnetic stimulation really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry2011;69(5):450‐6. [MEDLINE: BIOSIS:PREV201100154047] SlotemaCW , BlomJD , HoekHW , KahnRS , SommerIE . Can low‐frequency rtms really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large rct. Schizophrenia Research2010;117(2‐3):534. [MEDLINE: ISI:000276936801402] ">Slotema 2011</a>), although in <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a> participants on clozapine were excluded from the trial. In 12 studies participants used second‐generation antipsychotics: in <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a> and <a href="./references#CD006081-bbs2-0031" title="RosaMO , GattazWF , RosaMA , RumiDO , TavaresH , MyczkowskiM , et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. Journal of Clinical Psychiatry2007; Vol. 68, issue 10:1528‐32. ">Rosa 2007</a> all participants took clozapine; in <a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a> a significant number in each treatment group used clozapine; in <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a> and <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a> participants received risperidone; and in three studies all participants used second‐generation antipsychotics apart from one participant in the TMS group who used first‐generation antipsychotics (<a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>). Six studies did not report whether antipsychotics were used in the study (<a href="./references#CD006081-bbs2-0004" title="BrunelinJ , PouletE , BediouB , KallelL , DaleryJ , D'amatoT , et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. Schizophrenia Research2006;81(1):41‐5. [EMBASE 2005578713] ">Brunelin 2006</a>; <a href="./references#CD006081-bbs2-0020" title="LeeS‐H , KimW , ChungY‐C , JungK‐H , BahkW‐M , JunT‐Y , et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment‐refractory auditory hallucinations. Neuroscience Letters2005;376(3):177‐81. [MEDLINE: 15721217; EMBASE 2005083871] ">Lee 2005</a>; <a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>) and in the remaining studies all participants received antipsychotics, but the type was not reported. </p> </section> <section id="CD006081-sec-0123"> <h5 class="title">7. Outcomes</h5> <p>A variety of scales, used to assess clinical response and cognitive performance, are described in <a href="./appendices#CD006081-sec-0237">Appendix 1</a>. They assessed global state, mental state, cognitive state, adverse events and quality of life. </p> </section> <section id="CD006081-sec-0124"> <h5 class="title">8. Missing outcomes</h5> <p>No usable data were available for a number of outcomes, including adverse events, hospital and service outcomes, satisfaction with care, and economic outcomes. </p> </section> </section> <section id="CD006081-sec-0125"> <h4 class="title">Excluded studies</h4> <p>We excluded 58 studies. Reasons for exclusion were that 20 studies were not randomised controlled trials; one study was not randomised and the number of participants was less than five (<a href="./references#CD006081-bbs2-0064" title="HoffmanRE , BermanRM , RoesslerE , BelgerA , KrystalJH , CharneyDS . Low‐frequency transcranial magnetic stimulation in patients reporting voices. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15‐20; Washington DC, USA. 1999. [MEDLINE: 91114065] ">Hoffman 1999</a>); one study used no allocation concealment (<a href="./references#CD006081-bbs2-0069" title="JandlM , SteyerJ , WeberM , LindenDE , RothmeierJ , MaurerK , et al. Treating auditory hallucination by transcranial magnetic stimulation: a randomized controlled cross‐over trial. Neuropsychobiology2006;53(2):63‐9. ">Jandl 2006</a>); one study included participants with depression and not schizophrenia (<a href="./references#CD006081-bbs2-0063" title="HaseyG . Repeated transcranial magnetic stimulation (rTMS) for severe depression. Stanley Foundation Research Programs2000. ">Hasey 2000</a>); one study used healthy controls (<a href="./references#CD006081-bbs2-0087" title="NCT01620086 . Effect of repetitive transcranial magnetic stimulation on resting state brain activity in schizophrenia. ClinicalTrials.gov/show/NCT01620086 2012 (accessed 25th July 2015). ">NCT01620086</a>); for 12 studies the intervention was transcranial direct current stimulation and not TMS (<a href="./references#CD006081-bbs2-0042" title="ACTRN12611000731998 . Transcranial direct current stimulation (tdcs) treatment for auditory hallucinations and thinking problems in schizophrenia. www.anzctr.org.au 2010 (accessed 25th July 2015). ">ACTRN12611000731998</a>; <a href="./references#CD006081-bbs2-0043" title="ACTRN12612000217808 . Non‐invasive brain stimulation and working memory enhancement in schizophrenia and healthy controls: Investigating transcranial direct current stimulation (tdcs) and transcranial alternating current stimulation (tacs). www.anzctr.org.au/ACTRN12612000217808.aspx 2012 (accessed 25th July 2015). ">ACTRN12612000217808</a>; <a href="./references#CD006081-bbs2-0044" title="ACTRN12612001112853 . Using transcranial direct current stimulation (tdcs) to improve working memory in schizophrenia and healthy controls: Investigating the role of current strength at three time points post stimulation. www.anzctr.org.au/ACTRN12612001112853.aspx 2012 (accessed 25th July 2015). ">ACTRN12612001112853</a>; <a href="./references#CD006081-bbs2-0048" title="BrunelinJ , MondinoM , GassabL , HaesebaertF , GahaL , Suaud‐ChagnyM‐F , et al. Examining transcranial direct‐current stimulation (tdcs) as a treatment for hallucinations in schizophrenia. American Journal of Psychiatry2012;169(7):719‐24. [MEDLINE: BIOSIS:PREV201200520535] ">Brunelin 2012</a>; <a href="./references#CD006081-bbs2-0078" title="MattaiA , MillerR , WeisingerB , GreensteinD , BakalarJ , TossellJ , et al. Tolerability of transcranial direct current stimulation in childhood‐onset schizophrenia. Brain Stimulation2011;4(4):275‐80. [MEDLINE: 22032743] ">Mattai 2011</a>; <a href="./references#CD006081-bbs2-0081" title="NCT00757497 . Transcranial direct current brain stimulation to treat patients with childhood‐onset schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">NCT00757497</a>; <a href="./references#CD006081-bbs2-0082" title="NCT00870909 . Transcranial direct current stimulation (tDCS) and hallucinations in schizophrenia. www.clinicaltrials.gov 2009 (accessed 25th July 2015). ">NCT00870909</a>; <a href="./references#CD006081-bbs2-0084" title="NCT01378078 . Transcranial direct current stimulation (tdcs) for treatment of negative syndrome in patients with schizophrenia. ClinicalTrials.gov/show/NCT01378078 2011 (accessed 25th July 2015). ">NCT01378078</a>; <a href="./references#CD006081-bbs2-0086" title="NCT01607840 . Effects of transcranial direct current stimulation in individuals with schizophrenia. ClinicalTrials.gov/show/NCT01607840 2012 (accessed 25th July 2015). ">NCT01607840</a>; <a href="./references#CD006081-bbs2-0088" title="NCT01623726 . Transcranial direct current stimulation (tdcs) as therapeutical strategy for negative symptoms in schizophrenia. ClinicalTrials.gov/show/NCT01623726 2012 (accessed 25th July 2015). ">NCT01623726</a>; <a href="./references#CD006081-bbs2-0092" title="RushbyJA , LooC , WeickertCS , WeickertTW . Effects of transcranial direct current stimulation on probabilistic feedback learning in people with schizophrenia. Schizophrenia Research2010;117(2‐3):177. ">Rushby 2010</a>; <a href="./references#CD006081-bbs2-0097" title="WeickertTW , RushbyJA , VercammenA , WeickertCS , LooCK . Effects of transcranial direct current stimulation on probabilistic feedback learning in people with schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1(1):16‐7. ">Weickert 2010</a>); for one study the intervention was an antidepressant plus fMRI and not TMS (<a href="./references#CD006081-bbs2-0083" title="NCT01041274 . DECIFER: DEpression and Citalopram In First Episode Recovery. www.clinicaltrials.gov 2009 (accessed 25th July 2015). ">NCT01041274</a>); for two studies both intervention and comparison arms included TMS (<a href="./references#CD006081-bbs2-0085" title="NCT01595503 . Transcranial magnetic stimulation for the treatment of auditory hallucinations in schizophrenia. ClinicalTrials.gov/show/NCT01595503 2012 (accessed 25th July 2015). ">NCT01595503</a>; <a href="./references#CD006081-bbs2-0096" title="SlotemaCW , BlomJD , DeWeijerAD , HoekHW , SommerIE . Priming does not enhance the efficacy of 1 hertz repetitive transcranial magnetic stimulation for the treatment of auditory verbal hallucinations: results of a randomized controlled study. Brain Stimulation2012;5(4):554‐9. ">Slotema 2012</a>); for one study the number of participants in each arm of the trial was less than five (<a href="./references#CD006081-bbs2-0095" title="Schonfeldt‐LecuonaC , GronG , WalterH , BuchlerN , WunderlichA , SpitzerM , et al. Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. Neuroreport2004;15(10):1669‐73. [CN‐00516247] ">Schonfeldt‐Lecuona 2004</a>); 16 studies provided insufficient data for use (<a href="./references#CD006081-bbs2-0045" title="AlvaG , CohenE , JinY , HighumDM , FlemingK , BunneyWE , et al. Differential effects of high and low frequency RTMS in schizophrenia. Schizophrenia Research2001;49(2, Suppl 1):219. ">Alva 2001</a>; <a href="./references#CD006081-bbs2-0046" title="ArendsM , MobascherA , KratzJ , BrinkmeyerJ , JännerM , AgelinkMW , et al. Left dorsolateral prefrontal high frequency repetitive transcranial magnetic stimulation (rtms) and cognition in schizophrenic patients. XIII World Congress of Psychiatry; 2005 10‐15th Sept; Cairo, Egypt. 2005. [P11.P065] ">Arends 2005</a>; <a href="./references#CD006081-bbs2-0047" title="BenitezJ , FitzgeraldPB , MarstonN , DeCastellaAR , KulkarniJ . A double‐blind sham controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Schizophrenia Bulletin2005;31:509. [116185] ">Benitez 2005</a>; <a href="./references#CD006081-bbs2-0051" title="CordesJ , MittrachM , KotrotsiosG , ArendsM , WölwerW , WintererG , et al. Effect of a treatment with 10 hz repetitive transcranial magnetic stimulation (rTMS) on the EEG alpha activity of schizophrenic patients. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3‐8; Washington DC, USA. 2008. ">Cordes 2008</a>; <a href="./references#CD006081-bbs2-0054" title="DaskalakisZ . Repetitive transcranial magnetic stimulation (RTMS) in the neurophysiology and treatment of schizophrenia. Schizophrenia Bulletin2007;33:402. ">Daskalakis 2007</a>; <a href="./references#CD006081-bbs2-0060" title="GrenierS , FouldrinG , AllioG , OpolczynskiG , ThibautF . Repetitive transcranial magnetic stimulation efficiency in treatment‐resistant auditory hallucinations. Schizophrenia Research2008;98:56. ">Grenier 2008</a>; <a href="./references#CD006081-bbs2-0061" title="HajakG , MarienhagenJ , LangguthB , WernerS , BinderH , EichhammerP . High‐frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychological Medicine2004;34(7):1157‐63. ">Hajak 2004</a>; <a href="./references#CD006081-bbs2-0062" title="HasanA , GuseB , HeineY , HeyerS , Schneider‐AxmannT , FalkaiP , et al. Effects of long‐term prefrontal repetitive transcranial magnetic stimulation on motor‐cortical excitability. European Archives of Psychiatry and Clinical Neuroscience2010;1:52. ">Hasan 2010</a>; <a href="./references#CD006081-bbs2-0065" title="HoffmanR , BoutrosN , PredaA , RachidF , KrystalJ . One hertz repetitive transcranial magnetic stimulation reduces auditory hallucinations in patients with schizophrenia. Proceedings of the 7th World Congress of Biological Psychiatry. 2001 Jul 1‐6; Berlin, Germany. HoffmanRE , BoutrosNN , HuS , BermanRM , KrystalJH , Charney‐DS . Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet2000;355(9209):1073‐5. [MEDLINE: 10744097] ">Hoffman 2000</a>; <a href="./references#CD006081-bbs2-0066" title="HoffmanRE , HawkinsKA , AndersonAW , BuchananR , WuK , HampsonM , et al. One hertz repetitive transcranial magnetic stimulation delivered to brain areas underlying speech perception reduces persistent auditory hallucinations. Schizophrenia Research2003;60(1, Suppl 1):285‐6. [MEDLINE: 22399428; 12511172] ">Hoffman 2003</a>; <a href="./references#CD006081-bbs2-0071" title="JinY , PotkinSG , HuertaS , AlvaG , KangP , BunneyWE . EEG‐guided RTMS improves negative symptoms in schizophrenia. Schizophrenia Research2003;60(1, Suppl 1):287‐8. [DOI: S0920996403804735; MEDLINE: 22399428] ">Jin 2003</a>; <a href="./references#CD006081-bbs2-0072" title="JinY , PotkinSG , KempAS , HuertaST , AlvaG , ThaiTM , et al. Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (TMS) on the negative symptoms of schizophrenia. Schizophrenia Bulletin2006;32(3):556‐61. ">Jin 2006</a>; <a href="./references#CD006081-bbs2-0076" title="LooCK , SainsburyK , MitchellP , Hadzi‐PavlovicD , SachdevPS . A sham‐controlled trial of left and right temporal rTMS for the treatment of auditory hallucinations. Psychological Medicine2010;40(4):541‐6. [MEDLINE: ISI:000276575300002] ">Loo 2010</a>; <a href="./references#CD006081-bbs2-0079" title="MobascherA , AgelinkMW , ArendsM , BrinkmeyerJ , JaennerM , HenningU , et al. Influence of high frequency repetitive transcranial magnetic stimulation (rTMS) on cardiovagal modulation and monoaminergic activity in schizophrenia. Schizophrenia Bulletin2005;31:514. ">Mobascher 2005</a>; <a href="./references#CD006081-bbs2-0089" title="PotkinS . A randomized, sham‐controlled trial of repetitive transcranial magnetic stimulation in schizophrenia. Stanley Foundation Research Programs2000. ">Potkin 2000</a>; <a href="./references#CD006081-bbs2-0091" title="HuberTJ , SchneiderU , RollnikJ . Gender differences in the effect of repetitive transcranial magnetic stimulation in schizophrenia. Psychiatry Research2003;120(1):103‐5. RollnikJD , HuberTJ , MogkH , SiggelkowS , KroppS , DenglerR , et al. High frequency repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex in schizophrenic patients. Neuroreport2000;11(18):4013‐5. [Biological Abstracts 00073700] ">Rollnik 2000</a>; <a href="./references#CD006081-bbs2-0094" title="SchneiderA . A 2‐week double‐blind, randomized controlled trial of repetitive transcranial magnetic stimulation in schizophrenia. Stanley Foundation Research Programs2001. ">Schneider 2001</a>); and one study was terminated as they were unable to recruit participants (<a href="./references#CD006081-bbs2-0080" title="NCT00517075 . Treatment of negative symptoms of schizophrenia with transcranial magnetic stimulation (TMS). www.clinicaltrials.gov 2007 (accessed 25th July 2015). ">NCT00517075</a>). We excluded <a href="./references#CD006081-bbs2-0073" title="JinY , KempAS , HuangY , ThaiTM , LiuZ , XuW , et al. Alpha EEG guided TMS in schizophrenia. Brain Stimulation2012;5(4):560‐8. ">Jin 2012</a> as data were not reported separately for temporoparietal and prefrontal TMS </p> <section id="CD006081-sec-0126"> <h5 class="title">Awaiting assessment</h5> <p>There is one study, <a href="./references#CD006081-bbs2-0100" title="MohrP , RodriguezM , NovakT , KopecekM , HoracekJ , HendrychovaY , et al. Repetitive transcranial magnetic stimulation and rehabilitation of cognitive functions in schizophrenia. European Psychiatry2007;22:S127. MohrP , RodriguezM , NovakT , KopecekM , HoracekJ , HendrychovaY , et al. Repetitive transcranial magnetic stimulation and rehabilitation of cognitive functions in schizophrenia. Psychiatrie (Stuttgart, Germany)2006;10:7‐15. ">Mohr 2006</a>, awaiting assessment because we could not find the full article. See <a href="./references#CD006081-sec-0252" title="">Characteristics of studies awaiting classification</a> for more details. </p> </section> <section id="CD006081-sec-0127"> <h5 class="title">Ongoing studies</h5> <p>We identified 18 ongoing studies, with 790 planned participants. One trial out of the 18 ongoing trials compares TMS with treatment as usual, and the remaining studies compare TMS with sham TMS, although one trial (<a href="./references#CD006081-bbs2-0114" title="NCT01370291 . Repetitive transcranial magnetic stimulation for first‐episode schizophrenia patients. ClinicalTrials.gov/show/NCT01370291 2011 (accessed 25th July 2015). ">NCT01370291</a>) plans to compare both treatments with and without the use of risperidone. Three studies use high‐frequency prefrontal TMS, five use low‐frequency temporoparietal TMS, but a further nine studies use other TMS procedures (deep‐coil TMS in one study, high‐frequency temporoparietal TMS in another, and theta burst stimulation TBS in seven). See <a href="./references#CD006081-sec-0253" title="">Characteristics of ongoing studies</a> for details of each study. </p> </section> </section> </section> <section id="CD006081-sec-0128"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="./references#CD006081-sec-0250" title="">Characteristics of included studies</a> for our judgements and motivation for risk of bias for each study, <a href="#CD006081-fig-0002">Figure 2</a> for an overview of our judgements of risk of bias for each study and <a href="#CD006081-fig-0003">Figure 3</a> for an overview of percentages of low, unclear and high risk of bias for each category. </p> <div class="figure" id="CD006081-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006081-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD006081-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006081-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006081-sec-0129"> <h4 class="title">Allocation</h4> <p>All included studies were reported as randomised. Seventeen studies adequately described the method of sequence generation (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>; <a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>; <a href="./references#CD006081-bbs2-0035" title="SlotemaCC , BlomJD , HoekHW , KahnRS , SommerIE . The efficacy of low‐frequency repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations may be low. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. SlotemaCW , BlomJD , DeWeijerAD , DiederenKM , GoekoopR , LooijestijnJ , et al. Can low‐frequency repetitive transcranial magnetic stimulation really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry2011;69(5):450‐6. [MEDLINE: BIOSIS:PREV201100154047] SlotemaCW , BlomJD , HoekHW , KahnRS , SommerIE . Can low‐frequency rtms really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large rct. Schizophrenia Research2010;117(2‐3):534. [MEDLINE: ISI:000276936801402] ">Slotema 2011</a>; <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>) and thus had a low risk of selection bias; the remaining studies did not provide details and were at unclear risk of selection bias. Seven studies were rated at low risk of bias as they had adequate allocation concealment (<a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; <a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>; <a href="./references#CD006081-bbs2-0035" title="SlotemaCC , BlomJD , HoekHW , KahnRS , SommerIE . The efficacy of low‐frequency repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations may be low. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. SlotemaCW , BlomJD , DeWeijerAD , DiederenKM , GoekoopR , LooijestijnJ , et al. Can low‐frequency repetitive transcranial magnetic stimulation really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry2011;69(5):450‐6. [MEDLINE: BIOSIS:PREV201100154047] SlotemaCW , BlomJD , HoekHW , KahnRS , SommerIE . Can low‐frequency rtms really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large rct. Schizophrenia Research2010;117(2‐3):534. [MEDLINE: ISI:000276936801402] ">Slotema 2011</a>). However, most studies had unclear allocation concealment. </p> </section> <section id="CD006081-sec-0130"> <h4 class="title">Blinding</h4> <p>Only seven studies adequately described the blinding of participants and personnel (<a href="./references#CD006081-bbs2-0004" title="BrunelinJ , PouletE , BediouB , KallelL , DaleryJ , D'amatoT , et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. Schizophrenia Research2006;81(1):41‐5. [EMBASE 2005578713] ">Brunelin 2006</a>; <a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>; <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a>; <a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>; <a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a>) and had a low risk of performance bias, and 34 studies had unclear risk of performance bias as the method of blinding participants and personnel was not adequately described. Most studies had a low risk of detection bias as the raters were adequately blinded, but with 13 studies at unclear risk of detection bias as they did not adequately describe blinding of outcome assessment (<a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a>; <a href="./references#CD006081-bbs2-0013" title="高志勤 , 余海鹰 , 崔雪莲 , 邱旭萍 . Low‐frequency repetitive transcranial magnetic stimulation treatment of chronic auditory hallucinations of schizophrenia efficacy soldiers] Google Translate [低频重复经颅磁刺激治疗军人精神分裂症慢性幻听疗效观察 []. People's Military Surgeon [人民军医]2010;53(1):5‐6. ">Gao 2010</a>; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>; <a href="./references#CD006081-bbs2-0019" title="KlirovaM , HoracekJ , NovakT , CermakJ , TislerovaB , TinteraJ . Clinical response of neuronavigated repetitive‐tms in the treatment of auditory hallucinations. European Neuropsychopharmacology2010;1:304‐5. KlirovaM , HorekJ , ErmkJ , NovkT , TilerovB . Clinical response of neuronavigated rtms in the treatment of auditory hallucinations. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal. 2009:S773. ">Klirova 2010</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>; <a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>; <a href="./references#CD006081-bbs2-0030" title="RenY‐P , ZhouD‐F , CaiZ‐J , HuangQ , LuL , ChenQ . Effects of high frequency repetitive transcranial magnetic stimulation on refractory negative symptom of schizophrenia: A double blind, randomized controlled trial. Chinese Mental Health Journal [中国心理卫生杂志]2011;25(2):89‐92. ">Ren 2011</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>; <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>). </p> </section> <section id="CD006081-sec-0131"> <h4 class="title">Incomplete outcome data</h4> <p>Most studies had an unclear risk of attrition bias because reasons for loss to follow‐up were not consistently indicated or were unreported. Nineteen studies had a low risk of attrition bias: three studies were analysed on an intention‐to‐treat basis (<a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a>; <a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>), seven studies adequately reported and dealt with attrition (<a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a>; <a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>) and nine studies reported no losses to follow‐up (<a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>; <a href="./references#CD006081-bbs2-0030" title="RenY‐P , ZhouD‐F , CaiZ‐J , HuangQ , LuL , ChenQ . Effects of high frequency repetitive transcranial magnetic stimulation on refractory negative symptom of schizophrenia: A double blind, randomized controlled trial. Chinese Mental Health Journal [中国心理卫生杂志]2011;25(2):89‐92. ">Ren 2011</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>; <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a>). Two studies had a high risk of attrition bias. For <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>, losses to follow‐up were not balanced between treatment groups, and <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> had a very high (44%) attrition rate. </p> </section> <section id="CD006081-sec-0132"> <h4 class="title">Selective reporting</h4> <p>Most studies had a low risk of reporting bias as they fully reported all stated outcomes. In five studies we considered the risk of reporting bias to be unclear (<a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; <a href="./references#CD006081-bbs2-0019" title="KlirovaM , HoracekJ , NovakT , CermakJ , TislerovaB , TinteraJ . Clinical response of neuronavigated repetitive‐tms in the treatment of auditory hallucinations. European Neuropsychopharmacology2010;1:304‐5. KlirovaM , HorekJ , ErmkJ , NovkT , TilerovB . Clinical response of neuronavigated rtms in the treatment of auditory hallucinations. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal. 2009:S773. ">Klirova 2010</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>). In 14 studies we considered the risk of reporting bias to be high, as some stated outcomes were not adequately reported (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a>; <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>; <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a>; <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>). We attempted to obtain any data which were not reported in published literature by contacting the authors. </p> </section> <section id="CD006081-sec-0133"> <h4 class="title">Other potential sources of bias</h4> <p>We rated 22 studies at low risk of bias, as we detected no other potential sources of bias. The remaining 19 had an unclear risk of bias as there was insufficient information to make a judgement. </p> </section> </section> <section id="CD006081-sec-0134"> <h3 class="title" id="CD006081-sec-0134">Effects of interventions</h3> <p>See: <a href="./full#CD006081-tbl-0001"><b>Summary of findings for the main comparison</b> TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia</a>; <a href="./full#CD006081-tbl-0002"><b>Summary of findings 2</b> TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia</a>; <a href="./full#CD006081-tbl-0003"><b>Summary of findings 3</b> PREFRONTAL TMS compared to SHAM TMS for schizophrenia</a>; <a href="./full#CD006081-tbl-0004"><b>Summary of findings 4</b> PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia</a> </p> <section id="CD006081-sec-0135"> <h4 class="title">COMPARISON 1: TEMPOROPARIETAL TMS vs SHAM TMS</h4> <p>Twenty trials randomised 692 participants and compared TEMPOROPARIETAL TMS (n = 399) vs SHAM TMS (n = 293) (<a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a>; <a href="./references#CD006081-bbs2-0004" title="BrunelinJ , PouletE , BediouB , KallelL , DaleryJ , D'amatoT , et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. Schizophrenia Research2006;81(1):41‐5. [EMBASE 2005578713] ">Brunelin 2006</a>; <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; <a href="./references#CD006081-bbs2-0008" title="FitzgeraldPB , BenitezJ , DaskalakisJZ , BrownTL , MarstonNA , DeCastellaA , et al. A double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations. Journal of Clinical Psychopharmacology2005;25(4):358‐62. ">Fitzgerald 2005</a>; <a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>; <a href="./references#CD006081-bbs2-0013" title="高志勤 , 余海鹰 , 崔雪莲 , 邱旭萍 . Low‐frequency repetitive transcranial magnetic stimulation treatment of chronic auditory hallucinations of schizophrenia efficacy soldiers] Google Translate [低频重复经颅磁刺激治疗军人精神分裂症慢性幻听疗效观察 []. People's Military Surgeon [人民军医]2010;53(1):5‐6. ">Gao 2010</a>; <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>; <a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0019" title="KlirovaM , HoracekJ , NovakT , CermakJ , TislerovaB , TinteraJ . Clinical response of neuronavigated repetitive‐tms in the treatment of auditory hallucinations. European Neuropsychopharmacology2010;1:304‐5. KlirovaM , HorekJ , ErmkJ , NovkT , TilerovB . Clinical response of neuronavigated rtms in the treatment of auditory hallucinations. Proceedings of the 17th European Psychiatric Association, EPA Congress; 2009 Jan 24‐28; Lisbon Portugal. 2009:S773. ">Klirova 2010</a>; <a href="./references#CD006081-bbs2-0020" title="LeeS‐H , KimW , ChungY‐C , JungK‐H , BahkW‐M , JunT‐Y , et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment‐refractory auditory hallucinations. Neuroscience Letters2005;376(3):177‐81. [MEDLINE: 15721217; EMBASE 2005083871] ">Lee 2005</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>; <a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a>; <a href="./references#CD006081-bbs2-0031" title="RosaMO , GattazWF , RosaMA , RumiDO , TavaresH , MyczkowskiM , et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. Journal of Clinical Psychiatry2007; Vol. 68, issue 10:1528‐32. ">Rosa 2007</a>; <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a>; <a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>; <a href="./references#CD006081-bbs2-0035" title="SlotemaCC , BlomJD , HoekHW , KahnRS , SommerIE . The efficacy of low‐frequency repetitive transcranial magnetic stimulation treatment for auditory verbal hallucinations may be low. Proceedings of the 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22‐26; New Orleans, LA. 2010. SlotemaCW , BlomJD , DeWeijerAD , DiederenKM , GoekoopR , LooijestijnJ , et al. Can low‐frequency repetitive transcranial magnetic stimulation really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial. Biological Psychiatry2011;69(5):450‐6. [MEDLINE: BIOSIS:PREV201100154047] SlotemaCW , BlomJD , HoekHW , KahnRS , SommerIE . Can low‐frequency rtms really relieve medication‐resistant auditory verbal hallucinations? Negative results from a large rct. Schizophrenia Research2010;117(2‐3):534. [MEDLINE: ISI:000276936801402] ">Slotema 2011</a>; <a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>; <a href="./references#CD006081-bbs2-0039" title="余海鹰 , 高志勤 , 金梅 , 孙剑 , 丁松柏 , 赵彬 , et al. Transcranial magnetic stimulation on prolactin levels in patients with schizophrenia [经颅磁刺激对精神分裂症患者催乳素水平的影响]. 东南国防医药2010; Vol. 12, issue 06:512‐4. 高志勤 , 余海鹰 , 金梅 , 孙剑 , 杨春 , 丁松柏 , et al. Low‐frequency repetitive transcranial magnetic stimulation on serum prolactin levels in patients with chronic schizophrenia [低频重复经颅磁刺激对慢性精神分裂症患者血清催乳素水平的影响]. 精神医学杂志2011;24(03):192‐5. ">Yu 2010</a>). </p> <section id="CD006081-sec-0136"> <h5 class="title">1.1 Global state</h5> <section id="CD006081-sec-0137"> <h6 class="title">a. Clinical improvement (CGI)</h6> <p>One study (<a href="./references#CD006081-bbs2-0010" title="高志勤 , 余海鹰 , 崔雪莲 , 金梅 , 邱旭萍 . [Low‐frequency repetitive transcranial magnetic stimulation treatment of schizophrenia and the effect of chronic auditory hallucinations follow‐up study] Google Translate [低频重复经颅磁刺激治疗精神分裂症慢性幻听的疗效及随访研究]. Shandong Archives of Psychiatry [山东精神医学]2009;22(4):257‐8. ">Gao 2009a</a>) found that the number of participants with a clinical improvement in global state did not differ between temporoparietal TMS and sham TMS when measured on the CGI scale; however they did not report the response criteria used to define clinical improvement (<a href="./references#CD006081-fig-0004" title="">Analysis 1.1</a>; 46 participants). </p> </section> <section id="CD006081-sec-0138"> <h6 class="title">b. Average scores for clinical improvement (CGI, high = poor)</h6> <p>Seven studies reported global state measured on the CGI scale and found a clear difference in favour of temporoparietal TMS (7 RCTs, n = 224, MD ‐0.50, 95% CI ‐0.76 to ‐0.23, <a href="./references#CD006081-fig-0005" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD006081-sec-0139"> <h5 class="title">1.2 Mental state</h5> <section id="CD006081-sec-0140"> <h6 class="title">a. General</h6> <section id="CD006081-sec-0141"> <p><b>i. Clinical improvement (PANSS &gt; 30% reduction)</b></p> <p><a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a> reported clinical improvement in mental state, defined as more than a 30% reduction in total PANSS score; the proportion of participants that had a clinical improvement in mental state did not differ between the treatment groups (<a href="./references#CD006081-fig-0006" title="">Analysis 1.3</a>; 51 participants). </p> </section> <section id="CD006081-sec-0142"> <p><b>ii. Average total score (various scales)</b></p> <p>Mental state was measured on the BPRS by <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a> (17 participants), which found no clear difference in scores between treatment groups. In contrast, total PANSS scores were clearly lower in the temporoparietal TMS group than the sham TMS group (5 RCTs, n = 127, MD ‐6.09, 95% CI ‐10.95 to ‐1.22, <a href="./references#CD006081-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD006081-sec-0143"> <p><b>iii. Average general psychopathology score (PANSS general)</b></p> <p>Four studies provided data regarding general psychopathology measured on the PANSS general subscale. There was no significant difference in scores between temporoparietal TMS and sham TMS (<a href="./references#CD006081-fig-0008" title="">Analysis 1.5</a>; 87 participants). </p> </section> </section> <section id="CD006081-sec-0144"> <h6 class="title">b. Specific</h6> <section id="CD006081-sec-0145"> <p><b>i. Average depression score (various scales)</b></p> <p><a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a> found that participants showed significantly less depression when measured on the SDS (1 RCT, n = 25, MD ‐5.59, 95% CI ‐11.57 to 0.39, <a href="./references#CD006081-fig-0009" title="">Analysis 1.6</a>) , but results were equivocal when measured on the HAMD by the same small study. <a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a> also reported data for depression and excitement factor on the BPRS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0006">Table 2</a>). </p> <div class="table" id="CD006081-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Skewed data ‐ Temporoparietal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: specific – BPRS depressive factor (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: specific – BPRS excitement factor (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ positive symptoms (SAPS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ hallucinations (AHRS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ positive symptoms (SAPS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ negative symptoms (SANS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state: CPT false items</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state: CPT missed items</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AHRS ‐ Auditory Hallucination Rating Scale<br/> BPRS ‐ Brief Psychiatric Rating Scale<br/> CPT ‐ Continuous Performance Test<br/> SANS ‐ Scale for Assessment of Negative Symptoms<br/> SAPS ‐ Scale for the Assessment of Positive Symptoms </p> </div> </div> </section> <section id="CD006081-sec-0146"> <p><b>ii. Hallucinations ‐ clinical improvement (various scales)</b></p> <p>Significantly more participants that received temporoparietal TMS showed a clinical improvement in hallucinations when defined as an HCS score of 5 or less (3 RCTs, n = 133, RR 2.26, 95% CI 1.18 to 4.35) or more than a 30% decrease on the AHRS (3 RCTs, n = 120, RR 2.99, 95% CI 1.12 to 7.98, <a href="./references#CD006081-fig-0010" title="">Analysis 1.7</a>). However, AHRS pooled data showed moderate heterogeneity (I² = 55%) and when we applied the random‐effects model the results became non‐significant. <a href="./references#CD006081-bbs2-0031" title="RosaMO , GattazWF , RosaMA , RumiDO , TavaresH , MyczkowskiM , et al. Effects of repetitive transcranial magnetic stimulation on auditory hallucinations refractory to clozapine. Journal of Clinical Psychiatry2007; Vol. 68, issue 10:1528‐32. ">Rosa 2007</a> reported “Reality” and “Attentional Salience” scores from the AHRS in figures, which showed a significant group effect (P = 0.0493 and P = 0.0360, respectively). </p> <p>We found no clear difference for clinical improvement in hallucinations when defined as improvement of one or more points on the PANSS hallucination item score, or more than a 30% reduction on the PSYRATS score. </p> </section> <section id="CD006081-sec-0147"> <p><b>iii. Average hallucinations score (various scales)</b></p> <p>Hallucinations scores were significantly lower in the temporoparietal TMS when measured on the HCS (3 RCTs, n = 162, MD ‐1.64, 95% CI ‐2.80 to ‐0.48) and by the PANSS hallucination item (4 RCTs, n = 125, MD ‐1.01, 95% CI ‐1.97 to ‐0.04, <a href="./references#CD006081-fig-0011" title="">Analysis 1.8</a>). However, the PANSS hallucination item data were highly heterogenous (I² = 81%), with no obvious clinical or methodological reason for the heterogeneity. Removal of the outlying study, <a href="./references#CD006081-bbs2-0013" title="高志勤 , 余海鹰 , 崔雪莲 , 邱旭萍 . Low‐frequency repetitive transcranial magnetic stimulation treatment of chronic auditory hallucinations of schizophrenia efficacy soldiers] Google Translate [低频重复经颅磁刺激治疗军人精神分裂症慢性幻听疗效观察 []. People's Military Surgeon [人民军医]2010;53(1):5‐6. ">Gao 2010</a>, reduced the heterogeneity (I² = 30%). </p> <p>In contrast, when hallucinations were measured using AVH‐related items from the PSYRATS and the AHRS, there was no significant difference in hallucination scores between treatment groups. However, the latter showed high levels of heterogeneity (I² = 62%), which we could not explain by differences in the treatment as all used low frequency (1 Hz). Furthermore, when we removed <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a>, which used deep temporoparietal TMS, the heterogeneity was unchanged. However, when we removed change data from the analysis (<a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>) the heterogeneity was reduced (I² = 20%). </p> <p><a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a> also reported endpoint data for hallucinations on the AHRS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0006">Table 2</a>). </p> </section> <section id="CD006081-sec-0148"> <p><b>iv. Average negative symptom scores (various scales)</b></p> <p>Negative symptoms were measured using the BPRS, PANSS negative and SANS scales. We found no significant difference in scores on the BPRS and PANSS; however one small study, <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>, which used high‐frequency temporoparietal TMS (10 Hz) showed a significant difference favouring temporoparietal TMS (1 RCT, n = 25, MD ‐23.58, 95% CI ‐37.06 to ‐10.1, <a href="./references#CD006081-fig-0012" title="">Analysis 1.9</a>). <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> also reported data for negative symptoms on the SANS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0006">Table 2</a>). </p> </section> <section id="CD006081-sec-0149"> <p><b>v. Positive symptoms ‐ clinical improvement (PANSS &gt; 30% reduction)</b></p> <p><a href="./references#CD006081-bbs2-0003" title="BlumbergerDM , ChristensenBK , ZipurskyRB , MollerB , ChenR , FitzgeraldPB , et al. MRI‐targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. Brain Stimulation2012;5(4):577‐85. NCT01386918 . Repetitive transcranial magnetic stimulation for refractory auditory hallucinations in schizophrenia. clinicaltrials.gov/ct2/show/NCT01386918 2011 (accessed 25th July 2015). ">Blumberger 2012</a> found no difference in clinical improvement of positive symptoms, which was defined as more than a 30% reduction in PANSS positive subscale score (<a href="./references#CD006081-fig-0013" title="">Analysis 1.10</a>; 51 participants). </p> </section> <section id="CD006081-sec-0150"> <p><b>vi. Average positive symptom score (various scales)</b></p> <p>Positive symptom scores were significantly lower in the temporoparietal TMS group than in the sham TMS group when measured on the PANSS positive subscale (11 RCTs, n = 333, MD ‐2.14, 95% CI ‐3.15 to ‐1.14, <a href="./references#CD006081-fig-0014" title="">Analysis 1.11</a>), but not significantly different when measured on the BPRS in one study (<a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a>; 17 participants) or the SAPS used by <a href="./references#CD006081-bbs2-0004" title="BrunelinJ , PouletE , BediouB , KallelL , DaleryJ , D'amatoT , et al. Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia. Schizophrenia Research2006;81(1):41‐5. [EMBASE 2005578713] ">Brunelin 2006</a> and <a href="./references#CD006081-bbs2-0015" title="HaoL , HuiL , RuiL , JijunW . The analysis of curative effect of negative symptoms in schizophrenic patients after the treatment of repetitive transcranial magnetic stimulation (rTMS) [重复经颅磁刺激治疗精神分裂症阴性症状的疗效分析]. Journal of Modern Electrophysiology [现代电生理学杂志]2008;15(3):134‐7. ">Hao 2008</a>. <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a> and <a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> also reported data for positive symptoms on the SAPS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0006">Table 2</a>). </p> </section> </section> </section> <section id="CD006081-sec-0151"> <h5 class="title">1.3 Cognitive state</h5> <p>Cognitive state was reported in three studies (<a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a>; <a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a>; <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a>) using 39 different measures. These data are reported in <a href="#CD006081-tbl-0007">Table 3</a>. Results were equivocal for all measures. <a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> also reported cognitive data on the CPT, but these data were skewed so we did not present them in <a href="#CD006081-tbl-0007">Table 3</a> (see <a href="#CD006081-tbl-0006">Table 2</a>). </p> <div class="table" id="CD006081-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Cognitive outcomes ‐ Temporoparietal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Change / endpoint data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> Sham TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Mean difference [95% CI]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Animal naming</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.67 [‐4.13 to 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CPT reaction time (ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>926.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐32.78 [‐110.89 to 45.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Controlled oral word association</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 [‐2.71 to 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT 1 score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 [‐1.57 to 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT B score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.33 [‐1.82 to 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT Long‐delay free recall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 [‐1.80 to 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT Recognition discriminative ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 [‐0.04 to 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT Short‐delay free recall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 [‐1.74 to 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT1‐5 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.28 [‐4.72 to 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit recall (distraction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 [‐1.03 to 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit recall (non‐distraction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.31 [‐3.81 to 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit symbol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 [‐4.25 to 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard, dominant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.92 [‐22.58 to 20.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard, nondominant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.54 [‐20.27 to 9.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporal orientation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 [‐1.04 to 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail Making A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 [‐2.99 to 8.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail Making B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.80 [‐34.25 to 22.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST completed categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.65 [‐2.16 to 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST completed categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 [‐0.25 to 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST conceptualisation level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.12 [‐19.39 to 13.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST CR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 [‐3.65 to 13.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST FM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.80 [‐4.37 to 11.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST NPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.70 [‐9.38 to 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PCLR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.60 [‐1.58 to 30.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.50 [‐25.14 to 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PNPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.10 [‐13.24 to 11.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 [‐11.08 to 13.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.80 [‐5.37 to 18.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST Ra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.39 [‐10.80 to 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST Re</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23 [‐10.87 to 15.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST Rp</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14.40 [‐27.46 to ‐1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST TA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 [‐16.31 to 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST TCFC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.30 [‐19.02 to 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST TE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.00 [‐27.84 to 9.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST time (sec)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.00 [‐156.36 to 144.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST selective error rate (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.80 [‐18.63 to 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST correct thinking time (sec)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.00 [‐59.47 to 83.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST error thinking time (sec)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐18.00 [‐115.79 to 79.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WRAT‐R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.80 [‐5.37 to 18.97]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CPT ‐ Continuous performance test<br/> CVLT ‐ California verbal learning test<br/> WCST ‐ Wisconsin card sorting test<br/> WRAT‐R ‐ wide range achievement test – reading </p> </div> </div> </section> <section id="CD006081-sec-0152"> <h5 class="title">1.4 Adverse effects</h5> <section id="CD006081-sec-0153"> <h6 class="title">a. General</h6> <section id="CD006081-sec-0154"> <p><b>i. Serious</b></p> <p><a href="./references#CD006081-bbs2-0025" title='NCT00308997 . Transcranial magnetic stimulation guided by neuroimaging for patients with persistent "voices". www.clinicaltrials.gov 2006 (accessed 25th July 2015). NCT00567281 . (Re‐enrollment) Bilateral repetitive transcranial magnetic stimulation trial for auditory hallucinations. www.clinicaltrials.gov 2007 (accessed 25th July 2015). '>NCT00308997</a> and <a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a> reported that there were no serious adverse events in either treatment group (<a href="./references#CD006081-fig-0015" title="">Analysis 1.12</a>; 130 participants). </p> </section> <section id="CD006081-sec-0155"> <p><b>ii. Leaving the study early</b></p> <p>The number of participants leaving the study early did not differ significantly between treatment groups (<a href="./references#CD006081-fig-0016" title="">Analysis 1.13</a>; 8 studies, 320 participants). </p> </section> </section> <section id="CD006081-sec-0156"> <h6 class="title">b. Specific</h6> <p>Participants receiving temporoparietal TMS clearly experienced more headaches (10 RCTs, n = 392, RR 2.65, 95% CI 1.56 to 4.50) and jaw and facial contraction (2 RCTs, n = 70, RR 8.32, 95% CI 1.13 to 61.17, <a href="./references#CD006081-fig-0017" title="">Analysis 1.14</a>) than those receiving sham TMS. Other adverse events ‐ concentration problems, earache, lightheadedness/dizziness, mild memory impairment/amnesia, restless legs, somatic discomfort, tingling sensation in the arm, worsening hallucinations/audible thoughts ‐ were not clearly different between treatment groups. </p> </section> </section> <section id="CD006081-sec-0157"> <h5 class="title">1.5 Quality of life</h5> <section id="CD006081-sec-0158"> <h6 class="title">a. Average score (Q‐LES‐Q, low = poor)</h6> <p><a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> measured quality of life on the Q‐LES‐Q and found no clear difference between deep temporoparietal TMS and sham TMS (<a href="./references#CD006081-fig-0018" title="">Analysis 1.15</a>; 20 participants). </p> </section> </section> </section> <section id="CD006081-sec-0159"> <h4 class="title">COMPARISON 2: TEMPOROPARIETAL TMS vs STANDARD TREATMENT</h4> <p>Two trials randomised 140 participants and compared TEMPOROPARIETAL TMS (n = 70) versus STANDARD TREATMENT (n = 70) (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>). In both studies the participants received first‐ and second‐generation antipsychotics in both treatment groups. </p> <section id="CD006081-sec-0160"> <h5 class="title">2.1 Global state</h5> <section id="CD006081-sec-0161"> <h6 class="title">a. Clinical improvement (CGI ≤2)</h6> <p><a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a> found that there was no clear difference in the number of participants experiencing clinical improvement when temporoparietal TMS and antipsychotics were compared to antipsychotic treatment alone (<a href="./references#CD006081-fig-0019" title="">Analysis 2.1</a>; 100 participants). </p> </section> </section> <section id="CD006081-sec-0162"> <h5 class="title">2.2 Mental state</h5> <section id="CD006081-sec-0163"> <h6 class="title">a. Average hallucinations score (AHRS)</h6> <p><a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a> reported data for hallucinations on the AHRS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0008">Table 4</a>). </p> <div class="table" id="CD006081-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Skewed data ‐ Temporoparietal TMS vs standard treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ hallucinations (AHRS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AHRS ‐ Auditory Hallucination Rating Scale</p> </div> </div> </section> </section> <section id="CD006081-sec-0164"> <h5 class="title">2.3 Adverse effects</h5> <section id="CD006081-sec-0165"> <h6 class="title">a. General ‐ leaving the study early</h6> <p>The number of participants leaving the study early was not clearly different between temporoparietal TMS and antipsychotics alone (<a href="./references#CD006081-fig-0020" title="">Analysis 2.2</a>; 140 participants). </p> </section> </section> </section> <section id="CD006081-sec-0166"> <h4 class="title">COMPARISON 3: PREFRONTAL TMS vs SHAM TMS</h4> <p>Seventeen trials randomised 502 participants and compared PREFRONTAL TMS (n = 266) versus SHAM TMS (n = 236) (<a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a>; <a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a>; <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a>; <a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>; <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a>; <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>; <a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>; <a href="./references#CD006081-bbs2-0030" title="RenY‐P , ZhouD‐F , CaiZ‐J , HuangQ , LuL , ChenQ . Effects of high frequency repetitive transcranial magnetic stimulation on refractory negative symptom of schizophrenia: A double blind, randomized controlled trial. Chinese Mental Health Journal [中国心理卫生杂志]2011;25(2):89‐92. ">Ren 2011</a>; <a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a>; <a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>). </p> <section id="CD006081-sec-0167"> <h5 class="title">3.1 Global state</h5> <section id="CD006081-sec-0168"> <h6 class="title">a. Average scores (various scales)</h6> <p>Three small studies (<a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>; <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>) measured global state on the CGI, CGI‐S, GAF and SCL‐90, none of which showed a significant effect between prefrontal TMS and sham TMS (<a href="./references#CD006081-fig-0021" title="">Analysis 3.1</a>; 85 participants). </p> </section> </section> <section id="CD006081-sec-0169"> <h5 class="title">3.2 Mental state</h5> <section id="CD006081-sec-0170"> <h6 class="title">a. General</h6> <section id="CD006081-sec-0171"> <p><b>i. Clinical improvement (&gt; 20% decrease in total PANSS score)</b></p> <p>Results from one small trial (<a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a>) show that more participants in the prefrontal TMS group had a clinical improvement in mental state than those that received sham TMS (1 RCT, n = 22, RR 0.14, 95% CI 0.02 to 0.98, <a href="./references#CD006081-fig-0022" title="">Analysis 3.2</a>). </p> </section> <section id="CD006081-sec-0172"> <p><b>ii. Average total score (various scales)</b></p> <p>Mental state was measured using the BPRS and PANSS scales. We found no clear difference in participants' mental state between treatment groups on either scale (<a href="./references#CD006081-fig-0023" title="">Analysis 3.3</a>; 219 participants). However, the pooled data for the PANSS scale were heterogeneous (I² = 68%). When we removed the low‐frequency trial (<a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>), the heterogeneity remained. Removing outlying trials, <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a> and <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>, eliminated the heterogeneity, but the studies account for more than 40% of the weight for this outcome and we therefore did not pool the data. </p> </section> <section id="CD006081-sec-0173"> <p><b>iii. Average general psychopathology score (PANSS, high=poor)</b></p> <p>Six studies reported data on general psychopathology of participants, measured on the PANSS scale. The pooled data were highly heterogenous (I² = 81%) and removal of the two low‐frequency trials (<a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>; <a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a>) did not reduce the heterogeneity. Removal of the outlying trials, <a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a> and <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>, eliminated the heterogeneity, but as these trials accounted for 36% of the weighting, we did not pool the data (<a href="./references#CD006081-fig-0024" title="">Analysis 3.4</a>; 199 participants). </p> </section> </section> <section id="CD006081-sec-0174"> <h6 class="title">b. Specific</h6> <section id="CD006081-sec-0175"> <p><b>i. Average depression score (various scales)</b></p> <p>Depression was reported on four scales by four different studies. There were no significant differences on the HDRS and SCL‐90 DEP subscale, whereas, when measured on the HAMD‐17 (1 RCT, n = 43, MD ‐2.40, 95% CI ‐3.88 to ‐0.92) and MADRS (1 RCT, n = 22, MD ‐4.36 95% CI ‐7.05 to ‐1.67), prefrontal TMS was efficacious when compared to sham TMS (<a href="./references#CD006081-fig-0025" title="">Analysis 3.5</a>). <a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a> and <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a> also reported data for depression on the Calgary depression scale (CDS) and Calgary depression rating scale (CDRS) respectively, but as these data are skewed we have not presented them in analyses (see <a href="#CD006081-tbl-0009">Table 5</a>). </p> <div class="table" id="CD006081-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Skewed data ‐ Prefrontal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> TMS N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sham TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sham TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sham TMS N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ negative symptoms (PANSS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific – depressive symptoms (CDS, high = poor )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ positive symptoms (PANSS, high = poor) (LOCF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Depression (CDRS, high = poor) (LOCF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CDRS ‐ Calgary depression rating scale<br/> CDS ‐ Calgary depression scale<br/> PANSS ‐ positive and negative symptoms scale<br/> LOCF ‐ last observation carried forward </p> </div> </div> <p>CDRS ‐ Calgary depression rating scale<br/> CDS ‐ Calgary depression scale </p> </section> <section id="CD006081-sec-0176"> <p><b>ii. Average hallucinations score (PANSS)</b></p> <p><a href="./references#CD006081-bbs2-0029" title="任艳萍 , 周东丰 , 蔡焯基 , 黄青 , 卢苓 , 陈琦 . Low‐frequency repetitive transcranial magnetic stimulation in the treatment of refractory auditory hallucinations of schizophrenia randomized double‐blind controlled study Google Translate [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的随机双盲对照研究]. Chinese Mental Health Journal [中国心理卫生杂志]2010;24(3):195‐7, 205. ">Ren 2010</a> found no difference in hallucinations between treatment groups (1 RCT, n = 25, MD ‐0.68, 95% CI ‐1.68 to 0.32, <a href="./references#CD006081-fig-0026" title="">Analysis 3.6</a>). </p> </section> <section id="CD006081-sec-0177"> <p><b>iii. Negative symptoms ‐ clinical improvement (&gt; 20% decrease in PANSS negative)</b></p> <p>One small study (<a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>) found no difference in the number of participants that experienced a clinical improvement in negative symptoms (<a href="./references#CD006081-fig-0027" title="">Analysis 3.7</a>; 16 participants). </p> </section> <section id="CD006081-sec-0178"> <p><b>iv. Average negative symptom score (various scales)</b></p> <p>Pooled data for 10 studies that reported negative symptoms on the PANSS positive subscale were highly heterogeneous. Removing the low‐frequency studies (<a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a>; <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>) did not reduce the heterogeneity. Removal of the outlying trials (<a href="./references#CD006081-bbs2-0011" title="高志勤 , 余海鹰 , 孙剑 , 邱旭萍 , 钟爱芳 , 祝育青 , et al. The effect of repetitive transcranial magnetic stimulation on serum prolactin levels and event‐related potential P300 [重复经颅磁刺激对催乳素及事件相关电位P300的影响]. Linchuang Jingshen Yixue Zazhi [临床精神医学杂志]2009;19(2):84‐7. ">Gao 2009b</a>; <a href="./references#CD006081-bbs2-0012" title="高志勤 , 余海鹰 , 金梅 , 邱旭萍 . [Repetitive transcranial magnetic stimulation on the negative symptoms of chronic schizophrenia soldiers and the efficacy of cognitive function] Google Translate [重复经颅磁刺激对军人慢性精神分裂症患者阴性症状及认知功能的疗效分析]. Sichuan Mental Health [四川精神卫生]2009;22(4):193‐5. ">Gao 2009c</a>) reduced the heterogeneity (I² = 16%), and results show no significant difference between treatment groups. When measured on the SANS, three small studies found that participants receiving prefrontal TMS had a significant improvement compared to sham TMS (3 RCTs, n = 71, MD ‐12.68, 95% CI ‐18.60 to ‐6.77, <a href="./references#CD006081-fig-0028" title="">Analysis 3.8</a>). <a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a> also reported data for negative symptoms on the PANSS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0009">Table 5</a>). </p> </section> <section id="CD006081-sec-0179"> <p><b>v. Average positive symptom score (various scales)</b></p> <p>Positive symptoms were not significantly different between treatment groups for 10 studies (279 participants) that used the PANSS positive subscale and one small study (<a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a>; 22 participants) on the SAPS (<a href="./references#CD006081-fig-0029" title="">Analysis 3.9</a>). <a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a> also reported data for positive symptoms on the PANSS, but these data were skewed so we have not presented them in analyses (see <a href="#CD006081-tbl-0009">Table 5</a>). </p> </section> <section id="CD006081-sec-0180"> <p><b>vi. Average psychotism score (SCL‐90 PSY)</b></p> <p><a href="./references#CD006081-bbs2-0017" title="HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal rTMS in schizophrenia. Nordic Journal of Psychiatry2002; Vol. 56:19. HoliMM , EronenM , ToivonenK , ToivonenP , MarttunenM , NaukkarinenH . Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin2004;30(2):429‐34. [MEDLINE: 15279057; EMBASE 2004274074] ">Holi 2004</a> also found no difference in psychotism measured on the SCL‐90 PSY subscale between prefrontal TMS and sham TMS (<a href="./references#CD006081-fig-0030" title="">Analysis 3.10</a>; 22 participants). </p> </section> </section> </section> <section id="CD006081-sec-0181"> <h5 class="title">3.3 Cognitive state</h5> <p>Cognitive effects were reported in four studies (<a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>; <a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>; <a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>), using 19 different measures. These data are reported in <a href="#CD006081-tbl-0010">Table 6</a>. Results were equivocal for most of the outcome measures, with limited evidence to suggest a beneficial effect of TMS for five cognitive test scores. One study (<a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a>) reported significantly increased cognitive test scores on average in the TMS arm compared with the control arm for four outcomes: Hopkins verbal learning test (HVLT)‐delayed recall (after two weeks follow‐up), controlled oral word association test (COWAT) (two weeks after TMS), and the Stroop test (within 24 hours of treatment and at two weeks follow‐up) . A second study (<a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a>) reported significantly increased scores for Wisconsin card sorting test (WCST) categories (for people with WCST categories pre‐treatment median ≤ 4). More trials are needed to confirm or refute the beneficial effects of these cognitive test outcomes. </p> <div class="table" id="CD006081-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cognitive outcomes ‐ Prefrontal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Change / endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> Sham TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Mean difference [95% CI]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AVLT (low = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 [‐6.58 to 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COWAT (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 [‐4.22 to 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COWAT (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.10 [0.77 to 9.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit span test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 [‐15.70 to 17.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard (seconds to completion) (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.50 [‐26.37 to 43.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard (seconds to completion) (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.50 [‐12.46 to 33.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ delayed recall (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 [‐1.75 to 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ delayed recall (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.10 [0.12 to 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ immediate recall (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 [‐0.86 to 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ immediate recall (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.40 [0.39 to 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroop test (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.00 [8.89 to 43.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroop test (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.40 [17.91 to 36.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail making test A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.56 [‐5.79 to 30.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail making test B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.10 [‐14.46 to 24.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Verbal fluency test (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.30 [‐4.60 to 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.85 [‐10.76 to 14.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST categories for participants with WCST categories pre &lt; median (= 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.93 [0.18 to 5.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST perseverative answers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐19.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.18 [‐7.50 to 27.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST perseverative mistakes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10 [‐8.64 to 14.84]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AVTL ‐ auditory verbal learning test<br/> COWAT ‐ controlled oral word association test<br/> HVLT ‐ Hopkins verbal learning test<br/> WCST ‐ Wisconsin card sorting test </p> </div> </div> </section> <section id="CD006081-sec-0182"> <h5 class="title">3.4 Adverse effects</h5> <section id="CD006081-sec-0183"> <h6 class="title">a. General</h6> <section id="CD006081-sec-0184"> <p><b>i. Leaving the study early</b></p> <p>The number of participants leaving the study was reported in eight studies and did not differ significantly between treatment groups (8 RCTs, n = 174, RR 1.19, 95% CI 0.56 to 2.50, <a href="./references#CD006081-fig-0032" title="">Analysis 3.12</a>). </p> </section> </section> <section id="CD006081-sec-0185"> <h6 class="title">b. Specific</h6> <section id="CD006081-sec-0186"> <p><b>i. Various</b></p> <p>Participants in the prefrontal TMS group experienced more headaches than those in the sham TMS group (6 RCTs, n = 164, RR 2.77, 95% CI 1.22 to 6.26), and more TMS‐related site discomfort or pain (2 RCTs, n = 42, RR 8.33, 95% CI 1.68 to 41.27, <a href="./references#CD006081-fig-0033" title="">Analysis 3.13</a>). <a href="./references#CD006081-bbs2-0006" title="CordesJ , ThunkerJ , AgelinkMW , ArendsM , MobascherA , WobrockT , et al. Effects of 10 hz repetitive transcranial magnetic stimulation (rtms) on clinical global impression in chronic schizophrenia. Psychiatry Research2010;177(1‐2):32‐6. [MEDLINE: 20378181] MittrachM , ThunkerJ , WintererG , AgelinkMW , RegenbrechtG , ArendsM , et al. The tolerability of rtms treatment in schizophrenia with respect to cognitive function. Pharmacopsychiatry2010;43(3):110‐7. NCT00169689 . Therapeutic and biological effects of high frequency repetitive transcranial magnetic stimulation (rTMS) in schizophrenia. www.clinicaltrials.gov 2005 (accessed 25th July 2015). ">Cordes 2010</a> reported no adverse events measured on the UKU side effect rating scale and <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a> reported no cognitive difficulties in either treatment group. <a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a> also found no significant difference in facial twitching and worsening of pre‐existing akathisia and OCD. </p> </section> <section id="CD006081-sec-0187"> <p><b>ii. Average scores (CSSES)</b></p> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> measured subjective side effects and cognitive complaints on the CSSES and found no significant differences between prefrontal TMS and sham TMS (<a href="./references#CD006081-fig-0034" title="">Analysis 3.14</a>; 17 participants). </p> </section> </section> </section> </section> <section id="CD006081-sec-0188"> <h4 class="title">COMPARISON 4: PREFRONTAL TBS TMS vs SHAM TMS</h4> <p>Three trials randomised 115 participants and compared PREFRONTALTBS TMS (n = 59) versus SHAM TMS (n = 56) (<a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>). </p> <section id="CD006081-sec-0189"> <h5 class="title">4.1 Global state</h5> <section id="CD006081-sec-0190"> <h6 class="title">a. Clinical improvement</h6> <p><a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a> found no difference in the number of participants showing a clinical improvement in global state between prefrontal TBS TMS and sham TMS (<a href="./references#CD006081-fig-0035" title="">Analysis 4.1</a>; 27 participants). </p> </section> </section> <section id="CD006081-sec-0191"> <h5 class="title">4.2 Mental state</h5> <section id="CD006081-sec-0192"> <h6 class="title">a. General</h6> <section id="CD006081-sec-0193"> <p><b>i. Average total score (PANSS, high = poor)</b></p> <p>Three studies (<a href="./references#CD006081-bbs2-0005" title="陈海莹 , 张志娟 , 王继军 , 陈月敏 , 项志清 , 施慎逊 , et al. Repetitive transcranial magnetic stimulation in the adjuvant treatment of patients with schizophrenia to explore the influence of eye movements and negative symptoms: a randomized, double‐blind, pseudo‐stimulus‐control study [重复经颅磁刺激辅助治疗对精神分裂症患者探索性眼球运动和阴性症状的影响:随机、双盲、伪刺激对照研究(英文)]. 上海精神医学2011; Vol. 23, issue 04:200‐6. ">Chen 2011</a>; <a href="./references#CD006081-bbs2-0040" title="张志娟 , 张新凯 , 李惠 , 钟晓莲 , 成祖伟 , 廖力维 , et al. Randomized, double‐blind study of repetitive transcranial magnetic stimulation treatment of negative symptoms of schizophrenia [重复经颅磁刺激治疗精神分裂症阴性症状的随机双盲研究]. 上海精神医学2010;22(05):262‐5. ">Zhang 2010</a>; <a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>) reported data for mental state on the PANSS scale and found that prefrontal TBS TMS was efficacious when compared to sham TMS (3 RCTs, n = 108, MD ‐5.71, 95% CI ‐9.32 to ‐2.10, <a href="./references#CD006081-fig-0036" title="">Analysis 4.2</a>). </p> </section> <section id="CD006081-sec-0194"> <p><b>ii. Average general psychopathology score (PANSS, high = poor)</b></p> <p>General psychopathology was also significantly better in the prefrontal TBS TMS group (3 RCTs, n = 108, MD ‐2.47, 95% CI ‐4.21 to ‐0.73, <a href="./references#CD006081-fig-0037" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD006081-sec-0195"> <h6 class="title">b. Specific</h6> <section id="CD006081-sec-0196"> <p><b>i. Average negative symptom score (PANSS, high = poor)</b></p> <p>Negative symptoms were significantly lower in the prefrontal TBS TMS group than in the sham TMS group when measured on the PANSS (3 RCTs, n = 108, MD ‐2.67, 95% CI ‐4.25 to ‐1.09) and the SANS (1 RCT, n = 27, MD ‐11.55, 95% CI ‐21.90 to ‐1.2, <a href="./references#CD006081-fig-0038" title="">Analysis 4.4</a>). </p> </section> <section id="CD006081-sec-0197"> <p><b>ii. Average positive symptom score (PANSS, high = poor)</b></p> <p>Positive symptoms were not significantly different between treatment groups (<a href="./references#CD006081-fig-0039" title="">Analysis 4.5</a>; 108 participants). </p> </section> </section> </section> <section id="CD006081-sec-0198"> <h5 class="title">4.3 Cognitive state</h5> <section id="CD006081-sec-0199"> <h6 class="title">a. Average scores on various measures</h6> <p>We found no difference in cognitive state between treatment groups when measured using the digit span test and the verbal fluency test in one small study (<a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a>) (<a href="./references#CD006081-fig-0040" title="">Analysis 4.6</a>; 39 participants). </p> </section> </section> <section id="CD006081-sec-0200"> <h5 class="title">4.4 Adverse effects</h5> <section id="CD006081-sec-0201"> <h6 class="title">a. General ‐ Leaving the study early</h6> <p>The number of participants leaving the study early did not differ between the treatment groups (<a href="./references#CD006081-fig-0041" title="">Analysis 4.7</a>; 2 RCTs, 76 participants). </p> </section> <section id="CD006081-sec-0202"> <h6 class="title">b. Specific</h6> <p>Participants did not experience significantly different numbers of adverse events (headaches or sleep disorder) between prefrontal TBS TMS and sham TMS (<a href="./references#CD006081-fig-0042" title="">Analysis 4.8</a>; 1 RCT, 27 participants). </p> </section> </section> </section> <section id="CD006081-sec-0203"> <h4 class="title">Unusable data</h4> <p><a href="./references#CD006081-bbs2-0073" title="JinY , KempAS , HuangY , ThaiTM , LiuZ , XuW , et al. Alpha EEG guided TMS in schizophrenia. Brain Stimulation2012;5(4):560‐8. ">Jin 2012</a> reported data for clinical improvement combined for the two TMS groups (frontal and parietal) in the study, and so could not be added to any of the comparisons on the analyses. Clinical improvement was defined as at least a 30% improvement in PANSS score; 17 of 41 patients responded to the TMS (42%), whereas three of 24 responded to sham TMS (12%). </p> </section> <section id="CD006081-sec-0204"> <h4 class="title">Sensitivity analysis</h4> <p>There were no losses to follow‐up for the outcome 'clinical improvement in global state' for temporoparietal TMS compared to sham TMS or standard treatment, and no studies reported on this outcome when prefrontal TMS was compared with sham TMS. For prefrontal TBS TMS versus sham TMS there were no differences when completer‐only data were compared with all randomised in an intention‐to‐treat analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006081-sec-0205" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006081-sec-0205">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006081-sec-0286">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006081-sec-0205"></div> <p>Overall the quality of the evidence was rated as <i>very low</i> based on the 'Summary of findings' tables (<a href="./full#CD006081-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD006081-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD006081-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD006081-tbl-0004">summary of findings Table 4</a>). </p> <section id="CD006081-sec-0206"> <h3 class="title" id="CD006081-sec-0206">Summary of main results</h3> <section id="CD006081-sec-0207"> <h4 class="title">COMPARISON 1: TEMPOROPARIETAL TMS VERSUS SHAM</h4> <p>Very low‐quality evidence from one small trial showed no evidence of effect of temporoparietal TMS compared to sham TMS for clinically improving global state. However, there is some very low‐quality evidence to show that global state scores on the CGI scale are superior with temporoparietal TMS. There is also very low‐quality evidence from the PANSS scale that temporoparietal TMS is superior to sham TMS in improving mental state. While there may be some benefits with TMS over sham TMS, the clinical significance of some of the scale‐driven data is unclear. Very low‐quality evidence shows that temporoparietal TMS does not affect cognitive state; however, participants receiving temporoparietal TMS experienced more headaches than those in the sham TMS group. No more participants left the study early in the temporoparietal TMS than the sham TMS group, but again, this is very low‐quality evidence. No studies reported whether participants were satisfied with their care. </p> </section> <section id="CD006081-sec-0208"> <h4 class="title">COMPARISON 2: TEMPOROPARIETAL TMS VERSUS STANDARD CARE</h4> <p>Limited low‐quality evidence shows that temporoparietal TMS is not superior to standard treatment (first‐ and second‐generation antipsychotic medication) in clinically improving global state, and the number of participants leaving the study early does not differ between temporoparietal TMS and standard treatment. No studies reported on participants' mental state and cognitive state, experience of adverse effects and whether they were satisfied with their care. </p> </section> <section id="CD006081-sec-0209"> <h4 class="title">COMPARISON 3: PREFRONTAL TMS VERSUS SHAM</h4> <p>We found no evidence that prefrontal TMS is superior to sham TMS in improving global state, mental state and cognitive state, although the quality of the evidence is very low. Prefrontal TMS does not cause more headaches than sham TMS, and the number of participants leaving the study early did not differ between treatment groups, but again the evidence is of very low quality. No studies reported whether participants were satisfied with their care. </p> </section> <section id="CD006081-sec-0210"> <h4 class="title">COMPARISON 4: PREFRONTAL TBS TMS VERSUS SHAM</h4> <p>Prefrontal TBS TMS is not superior to sham TMS in improving global state and cognitive state, but there is some evidence that it improves mental state, although the evidence is of very low quality. Prefrontal TBS TMS does not cause participants to experience more headaches or to leave the study earlier than sham TMS, but again this is from very low‐quality evidence. No studies reported whether participants were satisfied with their care. </p> </section> </section> <section id="CD006081-sec-0211"> <h3 class="title" id="CD006081-sec-0211">Overall completeness and applicability of evidence</h3> <section id="CD006081-sec-0212"> <h4 class="title">1. Duration</h4> <p>Studies reported substantial differences in the length of trials, which ranged from four days (<a href="./references#CD006081-bbs2-0023" title="McIntoshAM , SempleD , TaskerK , HarrisonLK , OwensDGC , JohnstoneEC , et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Research2004;127(1‐2):9‐17. ">McIntosh 2004</a>) to 10 weeks (<a href="./references#CD006081-bbs2-0037" title="NCT00736710 . rTMS effects on smoking cessation and cognition in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Neuropsychopharmacology2010;35:S163. WingVC , BacherI , DaskalakisZJ , GeorgeT . A preliminary study of repetitive transcranial magnetic stimulation for smoking cessation in schizophrenia. Proceedings of the 49th Annual Meeting of the American College of Neuropsychopharmacology; 2010 Dec 5‐9; Miami, Florida. 2010. WingVC , BacherI , WuBS , DaskalakisZJ , GeorgeTP . High frequency repetitive transcranial magnetic stimulation reduces tobacco craving in schizophrenia. Schizophrenia Research2012;139(1‐3):264‐6. ">Wing 2012</a>). This issue is therefore potentially problematic for comparison, and caution should be considered in relation to any conclusions. Difference in study length may arise from the nature of the population samples in terms of the associated high attrition rates. The lack of consistency across studies in relation to study length may also reflect the novel aspect of the intervention and the lack of a standardised procedure. We did not stratify the data by the different time periods specified in <a href="#CD006081-sec-0045">Types of outcome measures</a> in the protocol, as there were not enough data (see <a href="#CD006081-sec-0248">Differences between protocol and review</a>). </p> </section> <section id="CD006081-sec-0213"> <h4 class="title">2. Participants</h4> <p>Participants were consistently classified with schizophrenia or schizoaffective disorder, with most studies using a diagnosis according to the DMS‐IV. <a href="./references#CD006081-bbs2-0028" title='PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Erratum to "Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study" [Schizophrenia Research 95 (1‐3) (2007) 151‐157] (DOI:101016/jschres200706019). Schizophrenia Research2008;99:380‐1. PrikrylR , KasparekT , SkotakovaS , UstohalL , KucerovaH , CeskovaE . Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double‐blind, randomized controlled study. Schizophrenia Research2007;95(1‐3):151‐7. PrikrylR , KasperekT , KucerovaH , UstohalL , VenclikovaS , CeskovaE , et al. Has high frequency repetitive transcranial magnetic stimulation therapeutic potential in schizophrenia?. 26th Collegium Internationale Neuro‐Psychopharmacologicum Congress (CINP). 2008; Vol. 11:91. PrikrylR , UstohalL , KasparekT , KucerovaH , CeskovaE , SkotakovaS . Influencing negative symptoms of schizophrenia with repetitive transcranial magnetic stimulation: a pilot study. European Neuropsychopharmacology. Amsterdam: Elsevier, 2006; Vol. 16 Suppl.4:S444‐5. '>Prikryl 2007</a> reported the ICD‐10, and <a href="./references#CD006081-bbs2-0034" title="SchneiderA , SchneiderT , StarkH . Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: A 4‐week randomized placebo controlled study. Brain Stimulation2008;1(2):106‐11. ">Schneider 2008</a> reported the use of both a diagnosis of schizophrenia with at least one year prior hospitalisation. The sample groups included for review were therefore well matched. </p> </section> <section id="CD006081-sec-0214"> <h4 class="title">3. Control condition</h4> <p>A wide variety of sham TMS techniques were reported across the included studies. Although most studies reported use of the same stimulation as for active TMS, additional descriptions of this procedure varied from the edge of the coil resting at a 45 degree angle, a 90 degree angle, with one wing touching or with both wings touching. In addition further descriptions included a sham coil which produced identical sounds to the active TMS, and a sham coil which had a magnetically non‐translucent headpiece. Drawing a comparison across results and the interpretation of findings is therefore hindered. </p> <p>Surprisingly, there is very little information on TMS compared to other treatments for schizophrenia. No studies compared TMS with other physical methods of treatment such as electroconvulsive therapy (ECT), and two (out of 41 included) studies compared TMS with standard treatment. The standard treatment in these studies (<a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a>; <a href="./references#CD006081-bbs2-0022" title="刘晓军 . Low‐frequency repetitive transcranial magnetic stimulation bdnf control of the level of impact on the sera of patients with schizophrenia [低频重复经颅磁刺激对精神分裂症患者血清bdnf水平影响的对照研究]. 精神医学杂志2011;24(03):196‐9. ">Liu 2011</a>) was antipsychotics, although those given TMS also received them. </p> <p>One trial out of the 18 ongoing trials compares TMS with treatment as usual, and the remaining studies compare TMS with sham TMS, although one trial (<a href="./references#CD006081-bbs2-0114" title="NCT01370291 . Repetitive transcranial magnetic stimulation for first‐episode schizophrenia patients. ClinicalTrials.gov/show/NCT01370291 2011 (accessed 25th July 2015). ">NCT01370291</a>) plans to compare both treatments with and without the use of risperidone. This indicates that the evidence base for TMS is still being studied against sham TMS, before comparisons with active treatments can be envisaged. </p> </section> <section id="CD006081-sec-0215"> <h4 class="title">4. Intervention</h4> <p>The active TMS intervention in both the prefrontal and temporoparietal conditions varied substantially across studies in terms of stimulation intensity, length of stimulation, and location of TMS. Studies which conducted prefrontal TMS reported the greatest variations. Stimulation intensity included ranges of 1 Hz, 10% above threshold to 20 Hz at 80% motor threshold, and three studies used TBS of 50 Hz. Length of stimulation for prefrontal TMS studies ranged from two trains of one minute with a three‐minute gap (<a href="./references#CD006081-bbs2-0018" title="KleinE , KolskyY , PuyerovskyM , KorenD , ChistyakovA , FeinsodM . Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double blind sham controlled pilot study. Biological Psychiatry1999;46(10):1451‐4. [MEDLINE: 10578460; EMBASE 1999401053] ">Klein 1999</a>), to 40 trains of 2.5 seconds with a 30‐second gap (<a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a>) with a number of different variations across studies. Location of prefrontal TMS stimulation also differed, with reports of left prefrontal TMS, left dorsolateral prefrontal cortex TMS, right prefrontal TMS, and bilateral prefrontal TMS. For studies which used temporoparietal TMS, there was some consistency in that all but two studies reported using TMS stimulations of 1 Hz. However the level of motor threshold did vary, with reports of 20% below motor threshold to 100% motor threshold. As with the prefrontal TMS studies, in the case of temporoparietal TMS a wide variety of stimulation length was reported, which ranged from five sessions of one minute with one‐minute gaps (<a href="./references#CD006081-bbs2-0033" title="SabaG , VerdonCM , KalalouK , RocamoraJF , DumortierG , BenadhiraR , et al. Transcranial magnetic stimulation in the treatment of schizophrenic symptoms: a double blind sham controlled study. Journal of Psychiatric Research2006;40(2):147‐52. ">Saba 2006a</a>) to two session of 20 minutes each a day (<a href="./references#CD006081-bbs2-0036" title="VercammenA , KnegteringH , BruggemanR , WestenbroekHM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry2010;1(1):15. VercammenA , KnegteringH , BruggemanR , Westenbroek HannekeM , JennerJA , SlooffCJ , et al. Effects of bilateral repetitive transcranial magnetic stimulation on treatment resistant auditory‐verbal hallucinations in schizophrenia: a randomized controlled trial. Schizophrenia Research2009;114(1‐3):172‐9. [MEDLINE: 19679450] VercammenA , KnegteringH , LiemburgEJ , DenBoerJA , AlemanA . Functional connectivity of the temporo‐parietal region in schizophrenia: Effects of rtms treatment of auditory hallucinations. Journal of Psychiatric Research2010;44(11):725‐31. [MEDLINE: 20189190] ">Vercammen 2009a</a>).There was also more consistency with studies of temporoparietal TMS in regards to location, as all but one study reported left temporoparietal TMS, with the exception of <a href="./references#CD006081-bbs2-0020" title="LeeS‐H , KimW , ChungY‐C , JungK‐H , BahkW‐M , JunT‐Y , et al. A double blind study showing that two weeks of daily repetitive TMS over the left or right temporoparietal cortex reduces symptoms in patients with schizophrenia who are having treatment‐refractory auditory hallucinations. Neuroscience Letters2005;376(3):177‐81. [MEDLINE: 15721217; EMBASE 2005083871] ">Lee 2005</a> which reported also using right temporoparietal TMS. Comparing data within each intervention is therefore problematic, particularly for the prefrontal TMS for which the procedure varied more widely. </p> </section> <section id="CD006081-sec-0216"> <h4 class="title">5. Outcomes</h4> <p>Of the seven categories of predefined outcomes, six were addressed in both the prefrontal TMS and temporoparietal TMS interventions. No data were available for analysis in the categories of hospital and service outcomes, satisfaction with care, and economic outcomes. There was a lack of data for quality of life, with only one study reporting this outcome for temporoparietal TMS. Future trials should consider including mechanisms for collecting these additional data; however, the authors acknowledge the tension between doing limited good‐quality data collection at the expense of quantity. </p> </section> </section> <section id="CD006081-sec-0217"> <h3 class="title" id="CD006081-sec-0217">Quality of the evidence</h3> <p>This review includes 41 studies with 1473 participants. Although all studies were reported as randomised, most studies reported unclear allocation concealment (<a href="#CD006081-fig-0002">Figure 2</a> and <a href="#CD006081-fig-0003">Figure 3</a>). There is therefore a risk of selection bias due to a possible lack of good methods to conceal the allocation. Overall, only seven papers reported adequate allocation concealment. Most studies included in the review were described as double‐blind. However, only seven studies reported an adequate blinding procedure. This can influence both performance and attrition bias, and is of particular importance in such study designs, due to the use of subjective measures. In many studies data were not fully reported and we had to contact authors in order to obtain both means and standard deviations for individual measures. </p> <p>Overall, we judged the quality of the evidence to be low to very low. In general, the results were consistent, although scale data results for mental state showed some heterogeneity. We downgraded the evidence in the 'Summary of findings' tables mostly because of the risks of bias in the studies mentioned above, and the imprecision of the results due to wide confidence intervals. </p> </section> <section id="CD006081-sec-0218"> <h3 class="title" id="CD006081-sec-0218">Potential biases in the review process</h3> <p>We tried to identify all relevant trials in our search strategy. It is, however, possible that we may not have identified all studies. We are also aware the search date is old at time of publication and there may be new studies available. </p> <p>The extraction of data and the risk of bias assessments for the Chinese language studies were completed by only one review author. There is the possibility that this may have introduced some bias into the results, as it was not possible to cross‐check these data. </p> </section> <section id="CD006081-sec-0219"> <h3 class="title" id="CD006081-sec-0219">Agreements and disagreements with other studies or reviews</h3> <p>Previous research has found that TMS can significantly reduce symptoms of schizophrenia. However, not all studies have subsequently replicated these findings. This was also reflected in the findings of the current review, as although there was some evidence to support the benefit of TMS in schizophrenia, findings were inconsistent across measures.  </p> <p>This review concluded that there was limited evidence for temporoparietal TMS as superior to sham TMS in improving auditory hallucinations; two meta‐analyses of sham‐controlled studies are in agreement with this finding, both concluding that there was a large and significant effect size for improving auditory hallucinations (<a href="./references#CD006081-bbs2-0137" title="FreitasC , FregniF , Pascual‐LeoneA . Meta‐analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophrenia Research2009;108(1‐3):11‐24. ">Freitas 2009</a>; <a href="./references#CD006081-bbs2-0153" title="MathesonSL , GreenMJ , LooC , CarrVJ . Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: a systematic meta‐review. Schizophrenia Research2010;118(1‐3):201‐10. ">Matheson 2010a</a>). This review found limited evidence that temporoparietal TMS is superior to sham TMS for improving positive symptoms when measured on the PANSS scale; a meta‐analysis of sham‐controlled studies was in agreement, finding a large and significant effect size (<a href="./references#CD006081-bbs2-0137" title="FreitasC , FregniF , Pascual‐LeoneA . Meta‐analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophrenia Research2009;108(1‐3):11‐24. ">Freitas 2009</a>). </p> <p>Limited evidence that prefrontal TMS is superior to sham in improving negative symptoms has also been reported elsewhere in two meta‐analyses (<a href="./references#CD006081-bbs2-0132" title="Dlabac‐de LangeJ , KnegteringR , AlemanA . Repetitive transcranial magnetic stimulatoin for negative symptoms of schizophrenia: review and meta‐Analysis. Journal of Clinical Psychiatry2010;71(4):411‐8. ">Dlabac‐de Lange 2010</a>; <a href="./references#CD006081-bbs2-0137" title="FreitasC , FregniF , Pascual‐LeoneA . Meta‐analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophrenia Research2009;108(1‐3):11‐24. ">Freitas 2009</a>), the former finding a statistically significant improvement in an analysis of both PANSS and SANS, and the latter finding a non‐significant small effect size for negative symptoms. Further agreement that prefrontal TMS can be effective in improving negative symptoms has been reached in a follow‐up communication to a review (<a href="./references#CD006081-bbs2-0154" title="MathesonSL , GreenMJ , LooC , CarrVJ . A change in the conclusions of a recent systematic meta‐review: Repetitive transcranial magnetic stimulation is effective for the negative symptoms of schizophrenia. Schizophrenia Research2010;122(1‐3):276‐7. ">Matheson 2010b</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006081-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006081-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006081-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD006081-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 1 Global state: 1. Clinical improvement (CGI)." data-id="CD006081-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 1 Global state: 1. Clinical improvement (CGI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 2 Global state: 2. Average score for clinical improvement (CGI, high = poor)." data-id="CD006081-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 2 Global state: 2. Average score for clinical improvement (CGI, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: a. Clinical improvement (PANSS &gt; 30% reduction)." data-id="CD006081-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: a. Clinical improvement (PANSS &gt; 30% reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: b. Average total score (various scales)." data-id="CD006081-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: b. Average total score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 5 Mental state: 1. General: c. Average general psychopathology score (PANSS general, high = poor)." data-id="CD006081-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 5 Mental state: 1. General: c. Average general psychopathology score (PANSS general, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: a. Average depression score (various scales)." data-id="CD006081-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: a. Average depression score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: b.i. Hallucinations ‐ clinical improvement (various scales)." data-id="CD006081-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: b.i. Hallucinations ‐ clinical improvement (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: b.ii. Average hallucinations score (various scales)." data-id="CD006081-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: b.ii. Average hallucinations score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: c. Average negative symptom score (various scales)." data-id="CD006081-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: c. Average negative symptom score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: d.i. Positive symptoms ‐ clinical improvement (PANSS &gt; 30% reduction)." data-id="CD006081-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: d.i. Positive symptoms ‐ clinical improvement (PANSS &gt; 30% reduction). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 11 Mental state: 2. Specific: d.ii. Average positive symptom score (various scales)." data-id="CD006081-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 11 Mental state: 2. Specific: d.ii. Average positive symptom score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General: a. Serious." data-id="CD006081-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General: a. Serious. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 1. General: b. Leaving the study early." data-id="CD006081-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 1. General: b. Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific." data-id="CD006081-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 15 Quality of life: Average score (Q‐LES‐Q, low = poor)." data-id="CD006081-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 TEMPOROPARIETAL TMS vs SHAM TMS, Outcome 15 Quality of life: Average score (Q‐LES‐Q, low = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 1 Global state: Clinical improvement (CGI ≤ 2)." data-id="CD006081-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 1 Global state: Clinical improvement (CGI ≤ 2). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 2 Adverse effects: Leaving the study early." data-id="CD006081-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 TEMPOROPARIETAL TMS vs STANDARD TREATMENT, Outcome 2 Adverse effects: Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 1 Global state: Average score (various scales)." data-id="CD006081-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 1 Global state: Average score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 2 Mental state: 1. General: a. Clinical improvement (&gt; 20% decrease in total PANSS score)." data-id="CD006081-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 2 Mental state: 1. General: a. Clinical improvement (&gt; 20% decrease in total PANSS score). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: b. Average total score (various scales)." data-id="CD006081-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: b. Average total score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: c. Average general psychopathology score (PANSS, high = poor)." data-id="CD006081-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 4 Mental state: 1. General: c. Average general psychopathology score (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 5 Mental state: 2. Specific: a. Average depression score (various scales)." data-id="CD006081-fig-0025" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 5 Mental state: 2. Specific: a. Average depression score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: b. Average hallucinations score (PANSS, high = poor)." data-id="CD006081-fig-0026" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 6 Mental state: 2. Specific: b. Average hallucinations score (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: c. i. Negative symptoms ‐ clinical improvement (&gt; 20% decrease in PANSS negative)." data-id="CD006081-fig-0027" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 7 Mental state: 2. Specific: c. i. Negative symptoms ‐ clinical improvement (&gt; 20% decrease in PANSS negative). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: c. ii. Average negative symptom score (various scales)." data-id="CD006081-fig-0028" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 8 Mental state: 2. Specific: c. ii. Average negative symptom score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: d. Average positive symptom score (various scales)." data-id="CD006081-fig-0029" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 9 Mental state: 2. Specific: d. Average positive symptom score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: e. Average psychotism score (SCL‐90 PSY, high = poor)." data-id="CD006081-fig-0030" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 10 Mental state: 2. Specific: e. Average psychotism score (SCL‐90 PSY, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 11 Adverse effects: 1. General: a. Adverse events (UKU)." data-id="CD006081-fig-0031" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 11 Adverse effects: 1. General: a. Adverse events (UKU). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General: b. Leaving the study early." data-id="CD006081-fig-0032" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 12 Adverse effects: 1. General: b. Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 2. Specific: a. Various." data-id="CD006081-fig-0033" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 13 Adverse effects: 2. Specific: a. Various. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific: b. Average score (CSSES, high = poor)." data-id="CD006081-fig-0034" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 PREFRONTAL TMS vs SHAM TMS, Outcome 14 Adverse effects: 2. Specific: b. Average score (CSSES, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 1 Global state: Clinical improvement." data-id="CD006081-fig-0035" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 1 Global state: Clinical improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 2 Mental state: 1. General: a. Average overall mental state score (PANSS total, high = poor)." data-id="CD006081-fig-0036" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 2 Mental state: 1. General: a. Average overall mental state score (PANSS total, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: b. Average general psychopathology score (PANSS, high = poor)." data-id="CD006081-fig-0037" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 3 Mental state: 1. General: b. Average general psychopathology score (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 4 Mental state: 2. Specific: a. Average negative symptom score (various scales)." data-id="CD006081-fig-0038" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 4 Mental state: 2. Specific: a. Average negative symptom score (various scales). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 5 Mental state: 2. Specific: b. Average positive symptom score (PANSS, high = poor)." data-id="CD006081-fig-0039" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 5 Mental state: 2. Specific: b. Average positive symptom score (PANSS, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 6 Cognitive state: Average score (various measures)." data-id="CD006081-fig-0040" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 6 Cognitive state: Average score (various measures). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 7 Adverse effects: 1. Leaving the study early." data-id="CD006081-fig-0041" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 7 Adverse effects: 1. Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 8 Adverse effects: 2. Specific." data-id="CD006081-fig-0042" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 8 Adverse effects: 2. Specific. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006081-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/urn:x-wiley:14651858:media:CD006081:CD006081-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_t/tCD006081-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 1 Global state: Clinical improvement." data-id="CD006081-fig-0043" src="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS, Outcome 1 Global state: Clinical improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/media/CDSR/CD006081/image_n/nCD006081-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006081-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> TEMPOROPARIETAL TMS<br/> <b>Comparison:</b> SHAM TMS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SHAM TMS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TEMPOROPARIETAL TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> <br/> CGI<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 7</b> <br/> (0.38 to 128.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> very <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> <br/> CGI<br/> Follow‐up: after treatment to 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean scores for the sham TMS group ranged from 2.4 to 5.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global state score in the intervention groups was<br/> <b>0.5 lower</b> <br/> (0.76 to 0.23 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> PANSS<br/> Follow‐up: after treatment to 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state scores in the sham TMS group ranged from 63.92 to 85.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>6.09 lower</b> <br/> (10.95 to 1.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> <br/> Various measures<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state was reported in 3 studies using 39 different measures. Results were equivocal for all measures </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> <br/> Follow‐up: after treatment to 30 days </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>442<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were more headaches and jaw and facial contraction in the TMS group. Results for other adverse events ‐ concentration problems, earache, lightheadedness, mild amnesia, restless legs, somatic discomfort, tingling sensation in the arm, worsening hallucinations ‐ were equivocal </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>152 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>118 per 1000</b> <br/> (70 to 200) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/> (0.46 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>320<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>low</b><sup>5,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported on this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies for pooled data and the control group risk for single studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ this study had an unclear risk of bias for randomisation, allocation concealment, blinding and incomplete outcome data. Downgraded one level.<br/> <sup>2</sup>Imprecision: very serious ‐ there were very few participants and very few events; there are wide confidence intervals that include both appreciable benefit and appreciable harm. Downgraded two levels<br/> <sup>3</sup>Risk of bias: very serious ‐ five studies had an unclear risk of bias for randomisation, six for allocation concealment, four studies for blinding of participants and four blinding of outcome assessors. One study had a high risk of bias for incomplete outcome data. Downgraded two levels.<br/> <sup>4</sup>Risk of bias: serious ‐ four studies had an unclear risk of bias for randomisation, five for allocation concealment, four for blinding of participants and two for blinding of outcome assessors. Three studies also had an unclear risk for incomplete outcome data. Downgraded one level.<br/> <sup>5</sup>Imprecision: serious ‐ there are wide confidence intervals for this outcome that include appreciable and non‐appreciable benefit. Downgraded one level.<br/> <sup>6</sup>Imprecision: very serious ‐ different scales were used to measure this outcome, all had wide confidence intervals. Downgraded two levels.<br/> <sup>7</sup>Risk of bias: serious ‐ six studies had an unclear risk of bias for randomisation and nine for allocation concealment. All studies had an unclear risk of bias for blinding of participants and three for blinding of outcome assessors. Six studies also had an unclear risk for incomplete outcome data. Downgraded one level.<br/> <sup>8</sup>Risk of bias: serious ‐ six studies had an unclear risk of bias for randomisation, five for allocation concealment, five studies for blinding of participants and four for blinding of outcome assessment. One study had a high risk of bias for incomplete outcome data. Downgraded one level.<br/> <sup>9</sup>Imprecision: very serious ‐ there are wide confidence intervals for this outcome that include appreciable benefit and appreciable harm. Downgraded two levels. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">TEMPOROPARIETAL TMS compared to SHAM TMS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006081-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> TEMPOROPARIETAL TMS<sup>1</sup> <br/> <b>Comparison:</b> STANDARD TREATMENT<sup>1</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> STANDARD TREATMENT</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> TEMPOROPARIETAL TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> <br/> CGI<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>620 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>738 per 1000</b> <br/> (564 to 973) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.91 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>86 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> <br/> (7 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> <br/> (0.08 to 1.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk is</b> the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Participants received first and second generation antipsychotics in both treatment groups<br/> <sup>2</sup>Risk of bias: serious ‐ this study had an unclear risk of bias for allocation concealment and blinding of participants and outcome assessors<br/> <sup>3</sup>Imprecision: serious ‐ the confidence intervals are wide and include both benefit and harm<br/> <sup>4</sup>Risk of bias: serious ‐ one study had an unclear risk of bias for randomisation and both studies for allocation concealment. One study had a unclear risk of bias for blinding of participants<br/> <sup>5</sup>Imprecision: very serious ‐ there were few participants and very few events; there are wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">TEMPOROPARIETAL TMS compared to STANDARD TREATMENT for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006081-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">PREFRONTAL TMS compared to SHAM TMS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PREFRONTAL TMS compared to SHAM TMS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> PREFRONTAL TMS<br/> <b>Comparison:</b> SHAM TMS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SHAM TMS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PREFRONTAL TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> <br/> Various scales<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 small studies measured global state on the CGI, CGI‐S, GAF and SCL‐90, none of which showed a significant treatment effect </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> PANSS<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was very high heterogeneity for this outcome, so we did not pool the data</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> <br/> Various measures<br/> Follow‐up: after treatment to 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state was reported in 4 studies using 19 different measures. Results were equivocal for all measures apart from 4 </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were more headaches and TMS‐related site discomfort or pain in the TMS group. Results for other adverse effects ‐ cognitive difficulties, facial twitching, worsening of pre‐existing akathisia and OCD ‐ were equivocal </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> <br/> Follow‐up: after treatment to 2 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>126 per 1000</b> <br/> (59 to 265) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.19</b> <br/> (0.56 to 2.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ two studies had an unclear risk of bias for randomisation and five for allocation concealment. Five studies had an unclear risk for blinding of participants and two for blinding of outcome assessors and incomplete outcome data.<br/> <sup>2</sup>Incosistency: very serious ‐ there was a very high heterogeneity for this outcome and we did not pool results<br/> <sup>3</sup>Risk of bias: serious ‐ two studies had an unclear risk of bias for randomisation and three for allocation concealment. All studies had an unclear risk for blinding of participants and two studies had an unclear risk for incomplete outcome data<br/> <sup>4</sup>Imprecision: serious ‐ different scales were used to measure this outcome, the majority had wide confidence intervals<br/> <sup>5</sup>Risk of bias: very serious ‐ five studies had an unclear risk of bias for randomisation and allocation concealment. All had an unclear risk for blinding of participants, and two for blinding of outcome assessors. Four had an unclear risk for incomplete outcome data<br/> <sup>6</sup>Imprecision: serious: there are wide confidence intervals<br/> <sup>7</sup>Risk of bias: serious ‐ seven studies had an unclear risk of bias for randomisation and five for allocation concealment. All had an unclear risk for blinding of participants, and three were unclear for blinding of outcome assessors. Four had a high or unclear risk for incomplete outcome data </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">PREFRONTAL TMS compared to SHAM TMS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006081-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with schizophrenia<br/> <b>Settings:</b> inpatients and outpatients<br/> <b>Intervention:</b> PREFRONTAL TBS TMS<br/> <b>Comparison:</b> SHAM TMS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> SHAM TMS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> PREFRONTAL TBS TMS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical improvement in global state</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.06</b> <br/> (0.21 to 77.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state score</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> <br/> PANSS<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean scores for the sham TMS group ranged from 67.6 to 68.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean mental state in the intervention groups was<br/> <b>5.71 lower</b> <br/> (9.32 to 2.1 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cognitive state</b> <br/> Various measures<br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This was measured on 2 scale, both showed equivocal results</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: general or specific</b> <br/> Follow‐up: after treatment </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No differences in headaches and sleep disorders</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects: Leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>139 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (10 to 242) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.36</b> <br/> (0.07 to 1.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Satisfaction with care</b> ‐ not reported </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies reported data for this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Risk of bias: serious ‐ there was an unclear risk of bias for allocation concealment and blinding<br/> <sup>2</sup>Imprecision: serious ‐ there were very few participants and very few events; the confidence intervals are wide<br/> <sup>3</sup>Imprecision: serious ‐ there are wide confidence intervals<br/> <sup>4</sup>Imprecision: serious ‐ this was measured on two scales by one study, both of which had wide confidence intervals </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">PREFRONTAL TBS TMS compared to SHAM TMS for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006081-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Magstim Company Limited</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Contact details</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mr John H Starzewski<br/> Managing Director<br/> Magstim Limited<br/> Spring Gardens<br/> Whitland SA34 0HR<br/> UK<br/> <br/> Telephone: +44 1994 241093<br/> URL: http://www.magstim.com/index.html </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Magstim Company Limited</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006081-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Skewed data ‐ Temporoparietal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0007" title="DeJesusDR , GilA , BarbosaL , LobatoMI , DaSilva MagalhaesPV , DeSouza FavalliGP , et al. A pilot double‐blind sham‐controlled trial of repetitive transcranial magnetic stimulation for patients with refractory schizophrenia treated with clozapine. Psychiatry Research2011;188(2):203‐7. [MEDLINE: BIOSIS:PREV201100512109] ">De Jesus 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: specific – BPRS depressive factor (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: specific – BPRS excitement factor (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0027" title="PouletE , BrunelinJ , BediouB , BationR , ForgeardL , DaleryJ , et al. Slow transcranial magnetic stimulation can rapidly reduce resistant auditory hallucinations in schizophrenia. Biological Psychiatry2005;57(2):188‐91. [MEDLINE: PUBMED 15652879; CN‐00513935] ">Poulet 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ positive symptoms (SAPS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ hallucinations (AHRS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0032" title="RosenbergO , GersnerR , KleinLD , KotlerM , ZangenA , DannonP . Deep transcranial magnetic stimulation add‐on for the treatment of auditory hallucinations: A double‐blind study. Annals of General Psychiatry2012;11:13. ">Rosenberg 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ positive symptoms (SAPS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ negative symptoms (SANS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state: CPT false items</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cognitive state: CPT missed items</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>AHRS ‐ Auditory Hallucination Rating Scale<br/> BPRS ‐ Brief Psychiatric Rating Scale<br/> CPT ‐ Continuous Performance Test<br/> SANS ‐ Scale for Assessment of Negative Symptoms<br/> SAPS ‐ Scale for the Assessment of Positive Symptoms </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Skewed data ‐ Temporoparietal TMS vs Sham TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006081-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Cognitive outcomes ‐ Temporoparietal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Change / endpoint data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> Sham TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Mean difference [95% CI]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Animal naming</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.67 [‐4.13 to 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CPT reaction time (ms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>926.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐32.78 [‐110.89 to 45.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Controlled oral word association</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 [‐2.71 to 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT 1 score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.07 [‐1.57 to 3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT B score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.33 [‐1.82 to 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT Long‐delay free recall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 [‐1.80 to 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT Recognition discriminative ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 [‐0.04 to 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT Short‐delay free recall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 [‐1.74 to 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CVLT1‐5 Total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.28 [‐4.72 to 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit recall (distraction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 [‐1.03 to 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit recall (non‐distraction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.31 [‐3.81 to 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit symbol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 [‐4.25 to 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard, dominant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.92 [‐22.58 to 20.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard, nondominant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.54 [‐20.27 to 9.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Temporal orientation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 [‐1.04 to 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail Making A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 [‐2.99 to 8.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail Making B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.80 [‐34.25 to 22.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST completed categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.65 [‐2.16 to 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST completed categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80 [‐0.25 to 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST conceptualisation level</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.12 [‐19.39 to 13.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST CR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.00 [‐3.65 to 13.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST FM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.80 [‐4.37 to 11.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST NPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐3.70 [‐9.38 to 1.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PCLR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.60 [‐1.58 to 30.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐5.50 [‐25.14 to 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PNPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐1.10 [‐13.24 to 11.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PPE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 [‐11.08 to 13.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST PR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.80 [‐5.37 to 18.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST Ra</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐3.39 [‐10.80 to 4.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST Re</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23 [‐10.87 to 15.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST Rp</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0038" title="徐亚秋 , 谢世平 , 杜经纶 . Clinical study of the treatment of schizophrenia refractory auditory hallucinations low frequency repetitive transcranial magnetic stimulation [低频重复经颅磁刺激治疗精神分裂症顽固性幻听的临床研究]. 临床精神医学杂志2011; Vol. 21, issue 03:177‐80. ">Xu 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14.40 [‐27.46 to ‐1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST TA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐4.00 [‐16.31 to 8.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST TCFC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐7.30 [‐19.02 to 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST TE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐9.00 [‐27.84 to 9.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST time (sec)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.00 [‐156.36 to 144.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST selective error rate (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐6.80 [‐18.63 to 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST correct thinking time (sec)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.00 [‐59.47 to 83.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WCST error thinking time (sec)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006081-bbs2-0021" title="LiuR , WangJ , LiuH , LiH . Comparative study for influence of rTMS on cognitive function in schizophrenia [重复经颅磁刺激治疗对精神分裂症认知功能影响的对照研究]. Shanghai Archives of Psychiatry [上海精神医学] [上海精神醫學]2008;20(5):257‐60, 307. ">Liu 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐18.00 [‐115.79 to 79.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WRAT‐R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0016" title='HoffmanRE , GueorguievaR , HawkinsKA , VarankoM , BoutrosNN , WuY , et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biological Psychiatry2005;58(2):97‐104. HoffmanRE , HawkinsKA , GueorguievaR , BoutrosNN , RachidF , CarrollK , et al. Transcranial magnetic stimulation of left temporoparietal cortex and medication‐resistant auditory hallucinations. Archives of General Psychiatry2003;60(1):49‐56. [MEDLINE: 22399428; 12511172] NCT00004980 . Randomized study of repetitive magnetic stimulation of speech processing brain areas in schizophrenic patients who hear "voices". www.clinicaltrials.gov 2000 (accessed 25th July 2015). NCT00042159 . TMS intervention development for auditory hallucinations. www.clinicaltrials.gov 2002 (accessed 25th July 2015). '>Hoffman 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.80 [‐5.37 to 18.97]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>CPT ‐ Continuous performance test<br/> CVLT ‐ California verbal learning test<br/> WCST ‐ Wisconsin card sorting test<br/> WRAT‐R ‐ wide range achievement test – reading </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Cognitive outcomes ‐ Temporoparietal TMS vs Sham TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006081-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Skewed data ‐ Temporoparietal TMS vs standard treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> TMS N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Sham TMS N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0001" title="BagatiD , NizamieSH , PrakashR . Effect of augmentatory repetitive transcranial magnetic stimulation on auditory hallucinations in schizophrenia: randomized controlled study. Australian and New Zealand Journal of Psychiatry2009;43(4):386‐92. [MEDLINE: 19296295] ">Bagati 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ hallucinations (AHRS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>AHRS ‐ Auditory Hallucination Rating Scale</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Skewed data ‐ Temporoparietal TMS vs standard treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006081-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Skewed data ‐ Prefrontal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> TMS N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sham TMS Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sham TMS SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Sham TMS N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0002" title="BarrMS , FarzanF , RajjiTK , VoineskosAN , BlumbergerDM , ArenovichT , et al. Can repetitive magnetic stimulation improve cognition in schizophrenia? Pilot data from a randomized controlled trial. Biological Psychiatry2013;73(6):510‐7. BarrMS , FarzanF , TranLC , FitzgeraldPB , DaskalakisZJ . A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation2011;3(5):337‐46. NCT01494623 . The effect of repetitive transcranial magnetic stimulation (rtms) on working memory. ClinicalTrials.gov/show/NCT01494623 2011 (accessed 25th July 2015). ">Barr 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ negative symptoms (PANSS, high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific – depressive symptoms (CDS, high = poor )</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD006081-bbs2-0009" title="FitzgeraldPB , HerringS , HoyK , McQueenS , SegraveR , KulkarniJ , etL . A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation2008;1(1):27‐32. FitzgeraldPB , HoyK , HerringS , McQueenS , KarpinskiA , DaskalakisZZ . The use of rtms and tdcs in the treatment of the positive, negative and cognitive symptoms of schizophrenia. Australian and New Zealand Journal of Psychiatry2010;1:16. ">Fitzgerald 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Specific ‐ positive symptoms (PANSS, high = poor) (LOCF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental state: Depression (CDRS, high = poor) (LOCF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CDRS ‐ Calgary depression rating scale<br/> CDS ‐ Calgary depression scale<br/> PANSS ‐ positive and negative symptoms scale<br/> LOCF ‐ last observation carried forward </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Skewed data ‐ Prefrontal TMS vs Sham TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006081-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cognitive outcomes ‐ Prefrontal TMS vs Sham TMS</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Change / endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b> Sham TMS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b> Mean difference [95% CI]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> N</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AVLT (low = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0026" title="NovakT , HoracekJ , MohrP , KopecekM , RodriguezM , SpanielF , et al. The double‐blind sham‐controlled study of high‐frequency rTMS (20Hz) fro negative symptoms in schizophrenia: a negative results. Neuroendocrinology Letters2006;27(1‐2):101‐5. ">Novak 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 [‐6.58 to 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COWAT (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 [‐4.22 to 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>COWAT (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.10 [0.77 to 9.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Digit span test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.5763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 [‐15.70 to 17.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard (seconds to completion) (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.50 [‐26.37 to 43.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Grooved pegboard (seconds to completion) (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.50 [‐12.46 to 33.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ delayed recall (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.00 [‐1.75 to 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ delayed recall (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.10 [0.12 to 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ immediate recall (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70 [‐0.86 to 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HVLT‐ immediate recall (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.40 [0.39 to 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroop test (within 24 hours of TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.00 [8.89 to 43.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroop test (2 weeks after TMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0024" title="McLoughlinD . Clinical effectiveness of repetitive transcranial magnetic stimulation (rTMS) for auditory hallucinations in schizophrenia‐ a randomised controlled trial. Unpublished report. 1994. [7th World Congress of Biological Psychiatry [CD‐ROM]: Conifer, Excerpta Medica Medical Communications BV, 2001 S019‐05] McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Biological Psychiatry2006;59(8 Suppl):34S. McLoughlinDM , MoggA , PurvisR , ErantiS , BrownR , ContellF , et al. Transcranial magnetic stimulation for negative symptoms in schizophrenia; a randomised pilot study. Proceedings of the 61st Annual Convention of the Society of Biological Psychiatry; 2006 May 18‐20; Toronto, Canada. Toronto, CANADA: Elsevier Science Inc, 2006:110. MoggA , PurvisR , ErantiS , ContellF , TaylorJP , NicholsonT , et al. Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: A randomized controlled pilot study. Schizophrenia Research2005;93(1‐3):221‐8. ">Mogg 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.40 [17.91 to 36.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail making test A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.56 [‐5.79 to 30.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trail making test B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.10 [‐14.46 to 24.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Verbal fluency test (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Endpoint</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0041" title="ZhengLN , GuoQ , LiH , LiC B , WangJJ . Effects of repetitive transcranial magnetic stimulation with different paradigms on the cognitive function and psychotic symptoms of schizophrenia patients. Beijing Da Xue Xue Bao2012;44:732‐6. ">Zheng 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.30 [‐4.60 to 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST categories</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.85 [‐10.76 to 14.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST categories for participants with WCST categories pre &lt; median (= 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.93 [0.18 to 5.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST perseverative answers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐19.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.18 [‐7.50 to 27.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WCST perseverative mistakes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006081-bbs2-0014" title="CordesJ , FalkaiP , GuseB , HasanA , Schneider‐AxmannT , ArendsM , et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham‐controlled, randomized multicenter study. European Archives of Psychiatry and Clinical Neuroscience2009;259(Suppl 2):189‐97. [MEDLINE: 19876678] GuseB , FalkaiP , GruberO , WhalleyH , GibsonL , HasanA , et al. The effect of long‐term high frequency repetitive transcranial magnetic stimulation on working memory in schizophrenia and healthy controls‐a randomized placebo‐controlled, double‐blind fmri study. Behavioural Brain Research2013;237(1):300‐7. NCT00783120 . Repetitive transcranial magnetic stimulation (rTMS) for the treatment of negative symptoms in schizophrenia. www.clinicaltrials.gov 2008 (accessed 25th July 2015). ">Guse 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.10 [‐8.64 to 14.84]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>AVTL ‐ auditory verbal learning test<br/> COWAT ‐ controlled oral word association test<br/> HVLT ‐ Hopkins verbal learning test<br/> WCST ‐ Wisconsin card sorting test </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cognitive outcomes ‐ Prefrontal TMS vs Sham TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/full#CD006081-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006081-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TEMPOROPARIETAL TMS vs SHAM TMS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: 1. Clinical improvement (CGI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.38, 128.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 2. Average score for clinical improvement (CGI, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.76, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. General: a. Clinical improvement (PANSS &gt; 30% reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.10, 10.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1. General: b. Average total score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.68 [‐12.98, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 PANSS total (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.09 [‐10.95, ‐1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 1. General: c. Average general psychopathology score (PANSS general, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.34 [‐5.26, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. Specific: a. Average depression score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 HAMD (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.92 [‐7.84, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 SDS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.59 [‐11.57, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2. Specific: b.i. Hallucinations ‐ clinical improvement (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 AHRS &gt;30% decrease in symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.99 [1.12, 7.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 HCS score ≤5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.26 [1.18, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 PANSS hallucination item improvement ≥1 point</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.43, 4.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 PSYRATS &gt; 30% reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.6 [0.20, 65.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2. Specific: b.ii. Average hallucinations score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 AHRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.11 [‐4.38, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 AVH‐related items PSYRATS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐3.38, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 HCS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.64 [‐2.80, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 PANSS hallucination item (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐1.97, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2. Specific: c. Average negative symptom score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.06 [‐7.15, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐1.87, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 SANS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐23.58 [‐37.06, ‐10.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2. Specific: d.i. Positive symptoms ‐ clinical improvement (PANSS &gt; 30% reduction) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.10, 10.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state: 2. Specific: d.ii. Average positive symptom score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 BPRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐2.78, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.14 [‐3.15, ‐1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 SAPS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.22 [‐7.86, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 1. General: a. Serious <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 1. General: b. Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 cardiovascular ‐ lightheaded/Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.45, 5.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 central nervous system ‐ tinnitus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.63 [0.19, 67.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 cognitive ‐ concentration problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.26, 9.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 cognitive ‐ mild memory impairment/amnesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.35, 24.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.5 movement disorder ‐ jaw and facial contraction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.32 [1.13, 61.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.6 movement disorder ‐ restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 35.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.7 psychiatric ‐ worsening hallucinations/audible Thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.55 [0.31, 20.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.8 others ‐ earache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 35.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.9 others ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.65 [1.56, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.10 others ‐ somatic discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.65, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.11 others ‐ tingling sensation in the arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.07, 35.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Quality of life: Average score (Q‐LES‐Q, low = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐14.26, 12.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">TEMPOROPARIETAL TMS vs SHAM TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006081-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TEMPOROPARIETAL TMS vs STANDARD TREATMENT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Clinical improvement (CGI ≤ 2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.91, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects: Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.08, 1.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">TEMPOROPARIETAL TMS vs STANDARD TREATMENT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006081-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PREFRONTAL TMS vs SHAM TMS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Average score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 CGI (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐0.15, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 CGI‐S (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.63, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 GAF (low = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [‐5.22, 12.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 SCL‐90 GSI (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.66, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. General: a. Clinical improvement (&gt; 20% decrease in total PANSS score) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. General: b. Average total score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1. General: c. Average general psychopathology score (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2. Specific: a. Average depression score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 HAMD‐17 (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐3.88, ‐0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 HDRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐0.95, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 MADRS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.36 [‐7.05, ‐1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 SCL‐90 DEP (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.61, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state: 2. Specific: b. Average hallucinations score (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.68, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state: 2. Specific: c. i. Negative symptoms ‐ clinical improvement (&gt; 20% decrease in PANSS negative) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.04, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state: 2. Specific: c. ii. Average negative symptom score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐4.68, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 SANS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.68 [‐18.60, ‐6.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state: 2. Specific: d. Average positive symptom score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.99, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 SAPS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐2.61, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state: 2. Specific: e. Average psychotism score (SCL‐90 PSY, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.48, 0.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1. General: a. Adverse events (UKU) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 1. General: b. Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.56, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 2. Specific: a. Various <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 cognition ‐ cognitive difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 movement disorder ‐ facial twitching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.59 [0.37, 117.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 movement disorder ‐ worsening of pre‐existing akathesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.71 [0.24, 90.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 psychiatric ‐ worsening of pre‐existing OCD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.71 [0.24, 90.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 other ‐ headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [1.22, 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 other ‐ TMS‐related site discomfort/pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.33 [1.68, 41.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 2. Specific: b. Average score (CSSES, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 cognitive complaints</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.6 [‐2.69, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 subjective side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐10.31, 6.51]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">PREFRONTAL TMS vs SHAM TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006081-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [0.21, 77.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1. General: a. Average overall mental state score (PANSS total, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.71 [‐9.32, ‐2.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1. General: b. Average general psychopathology score (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.47 [‐4.21, ‐0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 2. Specific: a. Average negative symptom score (various scales) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 PANSS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.67 [‐4.25, ‐1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SANS (high = poor)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.55 [‐21.90, ‐1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state: 2. Specific: b. Average positive symptom score (PANSS, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.64, 0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cognitive state: Average score (various measures) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 digit span test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [‐0.23, 4.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 verbal fluency test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [‐2.87, 7.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1. Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.07, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2. Specific <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.11, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.01, 6.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006081-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Global state: Clinical improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 including only people who completed the studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [0.21, 77.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Intention‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.41 [0.23, 84.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">SENSITIVITY ANALYSIS: PREFRONTAL THETA BURST STIMULATION TMS vs SHAM TMS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006081.pub2/references#CD006081-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006081.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD006081-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD006081-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006081-note-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006081-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD006081-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD006081-note-0003">日本語</a> </li> <li class="section-language"> <a class="" href="pt#CD006081-note-0002">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006081\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006081\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006081\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006081\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006081\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=qy4lqFNF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006081.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006081.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006081.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006081.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006081.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728859576"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006081.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728859579"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006081.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ecec21e8b9368',t:'MTc0MDcyODg1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 